US20110067126A1 - Gab1 involvement in glucose homeostasis regulation by hepatocytes - Google Patents
Gab1 involvement in glucose homeostasis regulation by hepatocytes Download PDFInfo
- Publication number
- US20110067126A1 US20110067126A1 US12/879,946 US87994610A US2011067126A1 US 20110067126 A1 US20110067126 A1 US 20110067126A1 US 87994610 A US87994610 A US 87994610A US 2011067126 A1 US2011067126 A1 US 2011067126A1
- Authority
- US
- United States
- Prior art keywords
- gab1
- glucose
- insulin
- gene
- mice
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 101100447914 Caenorhabditis elegans gab-1 gene Proteins 0.000 title claims abstract description 165
- 210000003494 hepatocyte Anatomy 0.000 title claims abstract description 21
- 230000014101 glucose homeostasis Effects 0.000 title abstract description 41
- 230000033228 biological regulation Effects 0.000 title abstract description 3
- 238000000034 method Methods 0.000 claims abstract description 67
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 106
- 239000008103 glucose Substances 0.000 claims description 103
- 241000699670 Mus sp. Species 0.000 claims description 83
- 210000004185 liver Anatomy 0.000 claims description 54
- 210000004027 cell Anatomy 0.000 claims description 51
- 239000003795 chemical substances by application Substances 0.000 claims description 43
- 108090000623 proteins and genes Proteins 0.000 claims description 32
- 238000012217 deletion Methods 0.000 claims description 18
- 230000037430 deletion Effects 0.000 claims description 18
- 230000014509 gene expression Effects 0.000 claims description 13
- 238000011830 transgenic mouse model Methods 0.000 claims description 12
- 241000699666 Mus <mouse, genus> Species 0.000 claims description 11
- 238000001727 in vivo Methods 0.000 claims description 11
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 10
- 230000008859 change Effects 0.000 claims description 9
- 208000013016 Hypoglycemia Diseases 0.000 claims description 8
- 230000007423 decrease Effects 0.000 claims description 7
- 210000000056 organ Anatomy 0.000 claims description 6
- 229930193140 Neomycin Natural products 0.000 claims description 4
- 108020004440 Thymidine kinase Proteins 0.000 claims description 4
- 229960004927 neomycin Drugs 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 3
- 241001529936 Murinae Species 0.000 claims description 2
- 230000002779 inactivation Effects 0.000 claims description 2
- 210000004962 mammalian cell Anatomy 0.000 claims description 2
- 150000001875 compounds Chemical class 0.000 abstract description 64
- 102100025087 Insulin receptor substrate 1 Human genes 0.000 abstract description 31
- 101710201824 Insulin receptor substrate 1 Proteins 0.000 abstract description 31
- 230000000694 effects Effects 0.000 abstract description 30
- 230000001404 mediated effect Effects 0.000 abstract description 18
- 230000001105 regulatory effect Effects 0.000 abstract description 9
- 101150024075 Mapk1 gene Proteins 0.000 abstract description 8
- 102100037740 GRB2-associated-binding protein 1 Human genes 0.000 abstract description 2
- 101710098687 GRB2-associated-binding protein 1 Proteins 0.000 abstract description 2
- 108091054455 MAP kinase family Proteins 0.000 abstract 1
- 102000043136 MAP kinase family Human genes 0.000 abstract 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 abstract 1
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 208
- 229940125396 insulin Drugs 0.000 description 103
- 102000004877 Insulin Human genes 0.000 description 101
- 108090001061 Insulin Proteins 0.000 description 101
- 210000004369 blood Anatomy 0.000 description 34
- 239000008280 blood Substances 0.000 description 34
- 238000006366 phosphorylation reaction Methods 0.000 description 32
- 108020004414 DNA Proteins 0.000 description 31
- 230000026731 phosphorylation Effects 0.000 description 31
- 230000037361 pathway Effects 0.000 description 27
- 238000012360 testing method Methods 0.000 description 27
- 102000004169 proteins and genes Human genes 0.000 description 20
- 239000000243 solution Substances 0.000 description 17
- 239000013598 vector Substances 0.000 description 17
- 108700028369 Alleles Proteins 0.000 description 16
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 16
- 239000007924 injection Substances 0.000 description 16
- 238000002347 injection Methods 0.000 description 16
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 16
- 125000003821 2-(trimethylsilyl)ethoxymethyl group Chemical group [H]C([H])([H])[Si](C([H])([H])[H])(C([H])([H])[H])C([H])([H])C(OC([H])([H])[*])([H])[H] 0.000 description 15
- 241001465754 Metazoa Species 0.000 description 15
- 238000004626 scanning electron microscopy Methods 0.000 description 15
- 230000011664 signaling Effects 0.000 description 15
- 229940090044 injection Drugs 0.000 description 14
- 101000652725 Drosophila melanogaster Transcription initiation factor TFIID subunit 5 Proteins 0.000 description 13
- 101000752722 Homo sapiens Apoptosis-stimulating of p53 protein 1 Proteins 0.000 description 13
- 101001120056 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit alpha Proteins 0.000 description 13
- 101001120097 Homo sapiens Phosphatidylinositol 3-kinase regulatory subunit beta Proteins 0.000 description 13
- 101001116549 Homo sapiens Protein CBFA2T2 Proteins 0.000 description 13
- 101001000998 Homo sapiens Protein phosphatase 1 regulatory subunit 12C Proteins 0.000 description 13
- 101000927796 Homo sapiens Rho guanine nucleotide exchange factor 7 Proteins 0.000 description 13
- 102100026169 Phosphatidylinositol 3-kinase regulatory subunit alpha Human genes 0.000 description 13
- 238000007423 screening assay Methods 0.000 description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 12
- 102100025092 Insulin receptor substrate 2 Human genes 0.000 description 11
- 101710201820 Insulin receptor substrate 2 Proteins 0.000 description 11
- 230000004913 activation Effects 0.000 description 11
- 206010012601 diabetes mellitus Diseases 0.000 description 11
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 10
- 238000004458 analytical method Methods 0.000 description 10
- 230000002440 hepatic effect Effects 0.000 description 10
- 238000003119 immunoblot Methods 0.000 description 10
- 239000000203 mixture Substances 0.000 description 10
- 230000004044 response Effects 0.000 description 10
- 239000000523 sample Substances 0.000 description 10
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 239000002502 liposome Substances 0.000 description 9
- 210000003205 muscle Anatomy 0.000 description 9
- 239000008194 pharmaceutical composition Substances 0.000 description 9
- 210000002027 skeletal muscle Anatomy 0.000 description 9
- 238000011282 treatment Methods 0.000 description 9
- 206010022489 Insulin Resistance Diseases 0.000 description 8
- 101150018665 MAPK3 gene Proteins 0.000 description 8
- 102000038030 PI3Ks Human genes 0.000 description 8
- 108091007960 PI3Ks Proteins 0.000 description 8
- 230000037396 body weight Effects 0.000 description 8
- 238000004113 cell culture Methods 0.000 description 8
- 230000008482 dysregulation Effects 0.000 description 8
- 238000007446 glucose tolerance test Methods 0.000 description 8
- 239000006166 lysate Substances 0.000 description 8
- 150000003839 salts Chemical class 0.000 description 8
- 230000019491 signal transduction Effects 0.000 description 8
- 102000003746 Insulin Receptor Human genes 0.000 description 7
- 108010001127 Insulin Receptor Proteins 0.000 description 7
- 108010091086 Recombinases Proteins 0.000 description 7
- 102000018120 Recombinases Human genes 0.000 description 7
- 239000012634 fragment Substances 0.000 description 7
- 230000009471 action Effects 0.000 description 6
- 239000013543 active substance Substances 0.000 description 6
- 238000012742 biochemical analysis Methods 0.000 description 6
- PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 description 6
- 238000012216 screening Methods 0.000 description 6
- 210000002966 serum Anatomy 0.000 description 6
- 239000000725 suspension Substances 0.000 description 6
- 230000001225 therapeutic effect Effects 0.000 description 6
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 description 6
- 102400001368 Epidermal growth factor Human genes 0.000 description 5
- 101800003838 Epidermal growth factor Proteins 0.000 description 5
- 239000002253 acid Substances 0.000 description 5
- 238000003556 assay Methods 0.000 description 5
- 239000002775 capsule Substances 0.000 description 5
- 239000000969 carrier Substances 0.000 description 5
- 229940116977 epidermal growth factor Drugs 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 238000001802 infusion Methods 0.000 description 5
- 238000007912 intraperitoneal administration Methods 0.000 description 5
- 239000003550 marker Substances 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 239000000546 pharmaceutical excipient Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 239000011780 sodium chloride Substances 0.000 description 5
- 230000000638 stimulation Effects 0.000 description 5
- 230000008685 targeting Effects 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 5
- 108010010803 Gelatin Proteins 0.000 description 4
- 238000010222 PCR analysis Methods 0.000 description 4
- 229920002472 Starch Polymers 0.000 description 4
- 210000000593 adipose tissue white Anatomy 0.000 description 4
- 210000000170 cell membrane Anatomy 0.000 description 4
- 230000002950 deficient Effects 0.000 description 4
- 239000008298 dragée Substances 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 239000000284 extract Substances 0.000 description 4
- 229920000159 gelatin Polymers 0.000 description 4
- 239000008273 gelatin Substances 0.000 description 4
- 235000019322 gelatine Nutrition 0.000 description 4
- 235000011852 gelatine desserts Nutrition 0.000 description 4
- 230000009229 glucose formation Effects 0.000 description 4
- 201000001421 hyperglycemia Diseases 0.000 description 4
- 230000001976 improved effect Effects 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 238000011068 loading method Methods 0.000 description 4
- 229920002521 macromolecule Polymers 0.000 description 4
- 238000004519 manufacturing process Methods 0.000 description 4
- 210000002569 neuron Anatomy 0.000 description 4
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 4
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 4
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 102000004196 processed proteins & peptides Human genes 0.000 description 4
- IPVFGAYTKQKGBM-BYPJNBLXSA-N 1-[(2r,3s,4r,5r)-3-fluoro-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-5-iodopyrimidine-2,4-dione Chemical compound F[C@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 IPVFGAYTKQKGBM-BYPJNBLXSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 238000011740 C57BL/6 mouse Methods 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 101000976075 Homo sapiens Insulin Proteins 0.000 description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 3
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 3
- 238000002105 Southern blotting Methods 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 238000010171 animal model Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 230000005754 cellular signaling Effects 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 230000007547 defect Effects 0.000 description 3
- 230000007812 deficiency Effects 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 229950008802 fialuridine Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 238000011813 knockout mouse model Methods 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004066 metabolic change Effects 0.000 description 3
- 239000002829 mitogen activated protein kinase inhibitor Substances 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 210000000496 pancreas Anatomy 0.000 description 3
- DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000700 radioactive tracer Substances 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 230000006798 recombination Effects 0.000 description 3
- 238000005215 recombination Methods 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 239000003381 stabilizer Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 235000000346 sugar Nutrition 0.000 description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 150000003626 triacylglycerols Chemical class 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 108010051219 Cre recombinase Proteins 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- 102000016607 Diphtheria Toxin Human genes 0.000 description 2
- 108010053187 Diphtheria Toxin Proteins 0.000 description 2
- 108010046276 FLP recombinase Proteins 0.000 description 2
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 2
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 2
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 2
- 229940124647 MEK inhibitor Drugs 0.000 description 2
- OFOBLEOULBTSOW-UHFFFAOYSA-N Malonic acid Chemical compound OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- 102000006601 Thymidine Kinase Human genes 0.000 description 2
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
- 229920004890 Triton X-100 Polymers 0.000 description 2
- 239000013504 Triton X-100 Substances 0.000 description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 210000003486 adipose tissue brown Anatomy 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000003190 augmentative effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 210000005013 brain tissue Anatomy 0.000 description 2
- 239000001768 carboxy methyl cellulose Substances 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 238000001311 chemical methods and process Methods 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 229950006137 dexfosfoserine Drugs 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 230000003292 diminished effect Effects 0.000 description 2
- 238000001378 electrochemiluminescence detection Methods 0.000 description 2
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 2
- -1 fatty acid esters Chemical class 0.000 description 2
- 239000010685 fatty oil Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 239000012458 free base Substances 0.000 description 2
- 238000010363 gene targeting Methods 0.000 description 2
- BRZYSWJRSDMWLG-CAXSIQPQSA-N geneticin Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](C(C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-CAXSIQPQSA-N 0.000 description 2
- 230000004190 glucose uptake Effects 0.000 description 2
- 238000013537 high throughput screening Methods 0.000 description 2
- 230000006801 homologous recombination Effects 0.000 description 2
- 238000002744 homologous recombination Methods 0.000 description 2
- 210000003016 hypothalamus Anatomy 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000007928 intraperitoneal injection Substances 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000008101 lactose Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 230000002503 metabolic effect Effects 0.000 description 2
- 230000002297 mitogenic effect Effects 0.000 description 2
- 239000013642 negative control Substances 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- MCYTYTUNNNZWOK-LCLOTLQISA-N penetratin Chemical compound C([C@H](NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H](CCCCN)NC(=O)[C@@H](NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](N)CCCNC(N)=N)[C@@H](C)CC)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(N)=O)C1=CC=CC=C1 MCYTYTUNNNZWOK-LCLOTLQISA-N 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 229920001184 polypeptide Polymers 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 238000005070 sampling Methods 0.000 description 2
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 239000000758 substrate Substances 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- YFDSDPIBEUFTMI-UHFFFAOYSA-N tribromoethanol Chemical compound OCC(Br)(Br)Br YFDSDPIBEUFTMI-UHFFFAOYSA-N 0.000 description 2
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 2
- 230000007306 turnover Effects 0.000 description 2
- BRZYSWJRSDMWLG-DJWUNRQOSA-N (2r,3r,4r,5r)-2-[(1s,2s,3r,4s,6r)-4,6-diamino-3-[(2s,3r,4r,5s,6r)-3-amino-4,5-dihydroxy-6-[(1r)-1-hydroxyethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol Chemical compound O1C[C@@](O)(C)[C@H](NC)[C@@H](O)[C@H]1O[C@@H]1[C@@H](O)[C@H](O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H]([C@@H](C)O)O2)N)[C@@H](N)C[C@H]1N BRZYSWJRSDMWLG-DJWUNRQOSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
- HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- 229920000936 Agarose Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 241001631457 Cannula Species 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 108010078791 Carrier Proteins Proteins 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 108020004705 Codon Proteins 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 238000012270 DNA recombination Methods 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015548 Euthanasia Diseases 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 102400000321 Glucagon Human genes 0.000 description 1
- 108060003199 Glucagon Proteins 0.000 description 1
- 102000058058 Glucose Transporter Type 2 Human genes 0.000 description 1
- 102000005720 Glutathione transferase Human genes 0.000 description 1
- 108010070675 Glutathione transferase Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 108010048671 Homeodomain Proteins Chemical group 0.000 description 1
- 102000009331 Homeodomain Proteins Human genes 0.000 description 1
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 1
- 102000013266 Human Regular Insulin Human genes 0.000 description 1
- 108010090613 Human Regular Insulin Proteins 0.000 description 1
- 206010062767 Hypophysitis Diseases 0.000 description 1
- 108091092195 Intron Proteins 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 1
- 239000000232 Lipid Bilayer Substances 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 235000019759 Maize starch Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100174728 Mus musculus Gab1 gene Proteins 0.000 description 1
- 229910020700 Na3VO4 Inorganic materials 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 108010089610 Nuclear Proteins Proteins 0.000 description 1
- 102000007999 Nuclear Proteins Human genes 0.000 description 1
- 102000007399 Nuclear hormone receptor Human genes 0.000 description 1
- 108020005497 Nuclear hormone receptor Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 108010016731 PPAR gamma Proteins 0.000 description 1
- 102000007079 Peptide Fragments Human genes 0.000 description 1
- 108010033276 Peptide Fragments Proteins 0.000 description 1
- 102100038825 Peroxisome proliferator-activated receptor gamma Human genes 0.000 description 1
- 108090000430 Phosphatidylinositol 3-kinases Proteins 0.000 description 1
- 102000003993 Phosphatidylinositol 3-kinases Human genes 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 101710130262 Probable Vpr-like protein Proteins 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 101710149951 Protein Tat Proteins 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- 239000012722 SDS sample buffer Substances 0.000 description 1
- 108091006299 SLC2A2 Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000011054 acetic acid Nutrition 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 210000000577 adipose tissue Anatomy 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940040563 agaric acid Drugs 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- RQPZNWPYLFFXCP-UHFFFAOYSA-L barium dihydroxide Chemical compound [OH-].[OH-].[Ba+2] RQPZNWPYLFFXCP-UHFFFAOYSA-L 0.000 description 1
- 229910001863 barium hydroxide Inorganic materials 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical compound [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 210000002459 blastocyst Anatomy 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000003544 deproteinization Effects 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 230000000667 effect on insulin Effects 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 1
- 230000001610 euglycemic effect Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 230000028023 exocytosis Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 210000003722 extracellular fluid Anatomy 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 230000008713 feedback mechanism Effects 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 235000012631 food intake Nutrition 0.000 description 1
- 230000037433 frameshift Effects 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 238000012215 gene cloning Methods 0.000 description 1
- 238000003205 genotyping method Methods 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 230000005182 global health Effects 0.000 description 1
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 1
- 229960004666 glucagon Drugs 0.000 description 1
- 229940093181 glucose injection Drugs 0.000 description 1
- 230000004153 glucose metabolism Effects 0.000 description 1
- 230000006377 glucose transport Effects 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 208000035474 group of disease Diseases 0.000 description 1
- 244000144993 groups of animals Species 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000009716 hepatic expression Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229940103471 humulin Drugs 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000003345 hyperglycaemic effect Effects 0.000 description 1
- 230000000910 hyperinsulinemic effect Effects 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000006362 insulin response pathway Effects 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000004155 insulin signaling pathway Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007913 intrathecal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 239000004922 lacquer Substances 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 1
- 108010052968 leupeptin Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 230000037356 lipid metabolism Effects 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 238000012317 liver biopsy Methods 0.000 description 1
- 210000005228 liver tissue Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000010369 molecular cloning Methods 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- LNOPIUAQISRISI-UHFFFAOYSA-N n'-hydroxy-2-propan-2-ylsulfonylethanimidamide Chemical compound CC(C)S(=O)(=O)CC(N)=NO LNOPIUAQISRISI-UHFFFAOYSA-N 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 229940098893 novolin r Drugs 0.000 description 1
- 108020004017 nuclear receptors Proteins 0.000 description 1
- 239000002773 nucleotide Substances 0.000 description 1
- 125000003729 nucleotide group Chemical group 0.000 description 1
- 238000007410 oral glucose tolerance test Methods 0.000 description 1
- 230000004768 organ dysfunction Effects 0.000 description 1
- 239000003791 organic solvent mixture Substances 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 108010043655 penetratin Proteins 0.000 description 1
- 239000000816 peptidomimetic Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 230000001817 pituitary effect Effects 0.000 description 1
- 210000003635 pituitary gland Anatomy 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 239000004014 plasticizer Substances 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 238000002731 protein assay Methods 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- ZHNFLHYOFXQIOW-LPYZJUEESA-N quinine sulfate dihydrate Chemical compound [H+].[H+].O.O.[O-]S([O-])(=O)=O.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21.C([C@H]([C@H](C1)C=C)C2)C[N@@]1[C@@H]2[C@H](O)C1=CC=NC2=CC=C(OC)C=C21 ZHNFLHYOFXQIOW-LPYZJUEESA-N 0.000 description 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 description 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 229940100486 rice starch Drugs 0.000 description 1
- 230000000630 rising effect Effects 0.000 description 1
- 238000012163 sequencing technique Methods 0.000 description 1
- 235000011803 sesame oil Nutrition 0.000 description 1
- 239000008159 sesame oil Substances 0.000 description 1
- 229920000260 silastic Polymers 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 150000003384 small molecules Chemical class 0.000 description 1
- 235000010413 sodium alginate Nutrition 0.000 description 1
- 239000000661 sodium alginate Substances 0.000 description 1
- 229940005550 sodium alginate Drugs 0.000 description 1
- FQENQNTWSFEDLI-UHFFFAOYSA-J sodium diphosphate Chemical compound [Na+].[Na+].[Na+].[Na+].[O-]P([O-])(=O)OP([O-])([O-])=O FQENQNTWSFEDLI-UHFFFAOYSA-J 0.000 description 1
- 229940048086 sodium pyrophosphate Drugs 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012439 solid excipient Substances 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical compound NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 235000019818 tetrasodium diphosphate Nutrition 0.000 description 1
- 239000001577 tetrasodium phosphonato phosphate Substances 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005945 translocation Effects 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- 210000003956 transport vesicle Anatomy 0.000 description 1
- 229950004616 tribromoethanol Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 230000001960 triggered effect Effects 0.000 description 1
- IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
- 238000011870 unpaired t-test Methods 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 210000001631 vena cava inferior Anatomy 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 229940100445 wheat starch Drugs 0.000 description 1
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical compound [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 description 1
- 229960001763 zinc sulfate Drugs 0.000 description 1
- 229910000368 zinc sulfate Inorganic materials 0.000 description 1
Images
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/66—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood sugars, e.g. galactose
Definitions
- This invention relates to the field of molecular biology and molecular medicine, and more specifically to proteins involved in blood glucose homeostasis and diabetes.
- a rise in blood glucose is normally followed by a rise in blood insulin. Insulin secretion is stimulated by many events associated with glucose intake. Primarily, insulin is secreted by the pancreas. High glucose concentration in the vicinity of the .beta.cells of the pancreas is sensed by the glucose transporter GLUT-2 and is carried into the cells. The glucose is modified and begins a signal transduction cascade that results in insulin exocytosis.
- Liver tissues play a central role in glucose homeostasis primarily orchestrated by insulin (Saltiel, A. R. & Kahn, C. R. Nature 414: 799-806 (2001), Michael, M. D. et al. Mol Cell 6: 87-97 (2000)), although it is not well understood how the insulin-elicited signals are tightly controlled in hepatocytes.
- insulin activates a four-subunit transmembrane receptor (insulin receptor) expressed on the surface of these tissue types.
- the activated insulin receptor phosphorylates and recruits different substrate adaptors such as the Insulin Receptor Substrate (IRS) family of proteins.
- IRS-1 and IRS-2 proteins are known to be positively required for relay of signals emanating from insulin receptor (Araki, E. et al. Nature 372: 186-90 (1994), Tamemoto, H. et al. Nature 372: 182-6 (1994), Withers, D. J. et al. Nature 391: 900-4 (1998)).
- Tyrosine phosphorylated IRS displays binding sites for numerous signaling partners.
- PI3K has a role in insulin function mainly characterized by the activation of the Akt/PKB and the PKC.zeta. cascades. These cascades are associated with glucagon synthesis and with glucose uptake. Glucose uptake is mediated by the translocation of glucose transport vesicles to the plasma membrane, which is regulated by numerous signal cascades including those discussed.
- Grb2-associated binder 1 (Gab1) is part of a family of adaptor proteins recruited by a wide variety of receptor tyrosine Kinases, such as the insulin receptor. Upon stimulation of the receptor by its cognate ligand, Gab is recruited to the plasma membrane, undergoes phosphorylation and functions as a multi protein assembly center Gab1 shares structural and functional homology with the IRS family of proteins, possessing a PH domain at the N-terminus, multiple tyrosine phosphorylation sites and proline-rich motifs for entertaining SH2- and SH3-containing proteins (Holgado-Madruga, M., et al. Nature 379: 560-4 (1996), Gu, H. & Neel, B.
- mice Homozygous Gab1 mutant mice are embryonic-lethal with the phenotype revealing an essential role of Gab1 in promoting signals from epidermal growth factor (EGF) and hepatocyte growth factor (HGF), etc (Sachs, M. et al. J Cell Biol 150: 1375-84. (2000), Itoh, M. et al. Mol Cell Biol 20: 3695-704 (2000)).
- EGF epidermal growth factor
- HGF hepatocyte growth factor
- the insulin signalling pathway is critical for the regulation of intracellular and blood glucose levels (glucose homeostasis), and dysregulation of glucose homeostasis is indicated in numerous disorders.
- diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both.
- type 1 and type 2 There are two main forms of diabetes; type 1 and type 2.
- Type 1 patients are unable to produce insulin, and thus must receive exogenous insulin to survive.
- type 2 patients have at least partially preserved insulin production, but often are insulin resistant.
- Insulin resistance is caused by defects that may arise at the insulin receptor or post-insulin receptor levels. Post-insulin receptor defects often involve signal transduction proteins.
- the primary treatment for diabetes is the delivery of exogenous insulin via pumps and/or injection.
- Total annual costs for treating diabetes is $132 billion, with $92 billion attributed to direct medical costs.
- a method of identifying a modulator of Gab1 includes providing a first group comprising cells that express Gab1 protein and a second group comprising cells modified to lack Gab1 protein expression; contacting the first group and second group with a candidate agent; comparing the extracellular glucose concentration of the first and second groups after contact with the candidate agent to a baseline value indicated by the difference in extracellular glucose concentration between the first and second groups without contact with the candidate agent; and identifying the candidate agent as a modulator of Gab1 if a change in glucose concentration between the first and second groups is found after contact with the candidate agent compared to the baseline value.
- the cells of the first and second groups comprise mammalian cells. In the same aspect, the cells of the first and second groups comprise murine cells. In the same aspect, the cells modified to lack Gab1 protein expression are from a transgenic mouse whose genome comprises a homozygous disruption of the endogenous Gab1 gene. In another aspect, the cells of the first and second groups are from the same organ type. In the same aspect, the organ type is liver.
- the providing and the contacting are performed in vitro. In an additional aspect, the providing and the contacting are performed in vivo.
- the first and second groups are mice.
- the second group is a transgenic mouse whose genome comprises a homozygous disruption of the endogenous Gab1 gene.
- the method further includes administering a known amount of glucose to the mice. In the same aspect, the extracellular glucose concentration is measured as plasma glucose levels.
- the candidate agent is identified as a positive modulator of Gab1 if the change in glucose concentration is an increase. In yet an additional aspect, the candidate agent is identified as a negative modulator of Gab1 if the change in glucose concentration is a decrease.
- a transgenic mouse whose genome includes a homozygous disruption of the endogenous Gab1 gene, wherein the disruption results in the functional inactivation of the Gab1 gene, and wherein the mouse exhibits hypoglycemia relative to a mouse whose genome comprises the functional endogenous Gab1 gene.
- the homozygous disruption is specifically in the hepatic cells of the mouse.
- the disruption in the Gab1 gene is a deletion of SEQ ID NO: 3.
- the Gab1 gene is replaced with a replacement gene.
- the replacement gene includes a neomycin resistance gene
- the replacement gene further includes a thymidine kinase gene.
- FIG. 1 a Generation of liver-specific Gab1 knockout mice: the targeting strategy. Genomic DNA fragments were cloned into the targeting vector as left, central and right arms. Three loxP sequences were marked by a black triangle (negative: HSV-TK; positive: PGK-NEO). Another negative selection marker, PGK-DT, was put outside of the right arm. The numbered boxes represent exons in the Gab1 gene. TK: thymidine kinase; NEO: neomycin; DT: diphtheria toxin.
- FIG. 1 b Southern blot analysis.
- genomic DNA was digested with BamHI and hybridized to the 32P-labelled 5′ probe.
- Three properly targeted ES cell clones flox/+ (F/+) showed a 6 kb band for the Gab1flox allele and a 10 kb band for the wild-type allele.
- the lower panel shows a 24 kb band for the wt allele and a 12 kb band for Gab1 fox allele, detected by the 3′ probe upon ApaI digestion of genomic DNA.
- FIG. 1 c PCR with A and B primers on DNA extracted from a Gab1flox/flox mouse (+/+; F/F) and a LGKO mouse.
- the Gab1flox allele produces a 630 by fragment and the Gab1-allele produces a 150 by band.
- Deletion of the loxP-floxed sequences was detected only in the liver (L), but not in the tail (T), skeletal muscle (M), pancreas (P), brown adipose tissue (Ba), white adipose tissue (Wa), hypothalamus (H), pituitary gland (Pi), and kidney (K).
- FIG. 1 d Immunoblot analysis of Gab1 protein expression in the liver, skeletal muscle, brain and white adipose tissue (Wa) isolated from mice of different genotypes: wild-type (WT), Albumin-Cre/+ (Cre/+), Gab1flox/flox (F/F), Alb-cre/+: Gab1flox/+ (Cre/+, F/+), and LGKO. Gab1 protein was barely detectable in the liver of LGKO mice.
- FIG. 1 e Immunoblot analysis of Gab1 expression in liver and skeletal muscle of control (Ctl, Gab1flox/flox) and LGKO mice at the age of 2-month and 1-year, respectively.
- FIGS. 2 a and 2 b Body weights of LGKO mice. Solid bars are for the control and open bars for LGKO mice. No statistically significant difference was observed between the two groups using the Student's t test analysis. Values are the means ⁇ SEM.
- M Male
- F Female.
- FIG. 3 d In vivo insulin sensitivity measured by Glucose infusion rate.
- N 8. *P ⁇ 0.05; **P ⁇ 0.01 for control versus LGKO. Values are the means ⁇ SEMs.
- FIG. 3 e In vivo insulin sensitivity measured by IS-GDR at the infusion rate of 12 mU/kg/min.
- FIG. 4 a Biochemical analysis of insulin signalling in LGKO mice.
- the phosphorylation levels of Akt at Ser473 (p-Akt) were quantified against Akt proteins amounts at different time-points in the liver and muscle. Shown are statistical data collected from 3-4 mice, by setting the value of the control at 2 min to 100, as well as a representative immunoblot. *P ⁇ 0.05; **P ⁇ 0.01;***P ⁇ 0.001 for control versus LGKO. Values are the means ⁇ SEMs.
- FIG. 4 b Insulin-induced tyrosine phosphorylation of IR.beta. in LGKO liver.
- Left panel is the statistical data of 3-4 experiments using different mice each time, by setting the control value at 2 min to 100.
- Right panel is a representative immunoblot result.
- Tyrosine phosphorylation of IR.beta. PY-IR
- IR.beta. IR.beta.
- Solid bars represent the Control (Ctl) mice and open bars LGKO mice. No statistical significances were found between the two groups using the Student's t test. Values are the means ⁇ SEMs.
- FIG. 4 c Biochemical analysis of insulin signalling in LGKO mice.
- FIG. 4 d Deletion of Gab1 leads to enhanced insulin signalling through IRS-1, -2 in hepatocytes.
- Mice were injected with 5 U insulin (Ins) (+) or saline ( ⁇ ) as a control via vena cava and liver extracts were prepared 2 min after injection.
- IRS-1 left panel or IRS-2 (right panel) were immunoprecipitated from liver lysates with specific antibodies and immunoblotted with antibodies against p85.alpha. subunit of PI3K, phosphotyrosine or against IRS-1, IRS-2 as a loading control.
- FIG. 4 e Biochemical analysis of insulin signalling in LGKO mice. Tyrosine phosphorylation of Gab1 in the liver were measured 2 min after vena cava injection with 5 U insulin (Ins) (+) or saline ( ⁇ ). Two mice were included in each group. *P ⁇ 0.05; **P ⁇ 0.01; ***P ⁇ 0.001 for control versus LGKO. Values are the means ⁇ SEMs.
- FIG. 4 f High levels of Gab1 tyrosine phosphorylation in hepatocytes induced by EGF or peroxovanadate. Tyrosine phosphorylation of Gab1 in the liver was measured 2 min after vena cava injection with EGF or peroxovanadate. Gab1 was immunoprecipitated from liver lysates with Gab1 antibody and immunoblotted with antibodies against phosphotyrosine or Gab1 as a loading control.
- FIG. 4 g Biochemical analysis of insulin signalling in LGKO mice. Gab1 phosphorylation on the p-YXXM motifs and its association with p85.alpha. in response to saline solution, insulin (ins), EGF, or peroxovanadate. *P ⁇ 0.05; **P ⁇ 0.01; *P ⁇ 0.001 for control versus LGKO. Values are the means ⁇ SEMs.
- FIG. 4 h Biochemical analysis of insulin signalling in LGKO mice. Insulin-induced p-Erk1/2 and p-IRS-1S612 were shown together with Erk2 and IRS-1 blots as loading controls. *P ⁇ 0.05; **P ⁇ 0.01; ***P ⁇ 0.001 for control versus LGKO. Values are the means ⁇ SEMs.
- FIG. 4 i Biochemical analysis of insulin signalling in LGKO mice. Inhibition of insulin-induced p-Erk1/2 and p-IRS-1S612 by PD98059 MEK inhibitor (left) or U0126 MEK inhibitor (right). *P ⁇ 0.05; **P ⁇ 0.01; ***P ⁇ 0.001 for control versus LGKO. Values are the means ⁇ SEMs.
- FIG. 5 Normal expression levels of proteins involved in insulin signaling. Immunoblot analysis was performed with lysates from liver or skeletal muscle of control and LGKO mice. Liver and muscle extracts were prepared after saline ( ⁇ ) or insulin (Ins) stimulation for 2 and 4 min, respectively (+). Deletion of Gab1 in the liver did not affect the hepatic expression of IRS-1, IRS-2, p85.alpha., Shp-2 or IR.beta.
- FIG. 6 Inventors model for Gab1 activity (a negative feedback mechanism) in insulin signaling in the liver through the insulin mediated Gab1 protein signaling pathway.
- Gab1 promotes activation of MapK (Erk), leading to the phosphorylation of the Ser612 residue on IRS-1 and suppressing tyrosine phosphorylation on IRS-1. This, in turn, attenuates insulin-initiated signals flowing through IRS-1/PI3K/Akt pathway.
- MapK MapK
- site-specific recombination refers to DNA transfer from a donor DNA or vector to an acceptor DNA or vector.
- lox sequence refers to a nucleotide sequence which undergoes recombination (e.g., DNA cross-over and exchange) when catalyzed by a recombinase, such as Cre, Flp or another member of the Int family of recombinases (Argos et al. (1986) EMBO J. 5: 433).
- Suitable lox sequences include, for example, the lox sequences recognized by Cre recombinase, and the frt sequences recognized by Flp recombinase.
- recombinase refers to any recombinase capable of catalyzing a site-specific recombination at a lox site.
- Suitable recombinases include, for example, Cre recombinase (Sauer et al. (1993) Methods in Enzymology 225: 898) and Flp recombinase (Buchholz et al. (1996) Nucl. Acids Res. 24:4256-4262; Buchholz et al. (1998) Nat. Biotechnol. 16:657-662).
- acceptor DNA and “acceptor vector,” are used interchangeably herein and refer to any DNA or vector which, preferably, is capable of integrating into the genome of a cell.
- the acceptor DNA or vector can be of viral origin, such as a retroviral vector or adeno-associated vector.
- the acceptor DNA or vector contains an exchange cassette (i.e., DNA which is replaced by DNA from the donor vector) and can also, optionally, contain a selectable (e.g., negative) marker gene.
- donor DNA and “donor vector” are used interchangeably herein and refer to any DNA or vector (e.g., circular plasmid DNA) containing DNA which is transferred to the acceptor DNA or vector via a recombinase-mediated exchange reaction.
- the donor DNA or vector comprises plasmid DNA and, optionally, also can contain a selectable (e.g., positive) marker gene.
- candidate compounds to test in the methods of the invention will depend on the application of the method. For example, one or a small number of candidate compounds can be advantageous in manual screening procedures, or when it is desired to compare efficacy among several predicted ligands, agonists or antagonists. However, it is generally understood that the larger the number of candidate compounds, the greater the likelihood of identifying a compound having the desired activity in a screening assay. Additionally, large numbers of compounds can be processed in high-throughput automated screening assays. Therefore, “one or more candidate compounds” can be, for example, 2 or more, such as 5, 10, 15, 20, 50 or 100 or more different compounds, such as greater than about 103, 105 or 107 different compounds, which can be assayed simultaneously or sequentially.
- the present invention relates to the discovery that Gab1 protein is a negative regulator of the glucose homeostasis pathway.
- Gab1 protein is a negative regulator of the glucose homeostasis pathway.
- MapK MapK
- LGKO Liver-specific Gab1 knockout mice were created to possess a conditional Gab1 knockout allele, a loxp-foxed allele of Gab1 (Gab1.sup.flox). Two loxP sites were inserted into introns flanking exon 3 of the Gab1 gene using homologous recombination in embryonic stem (ES) cells ( FIG. 1 a ).
- ES embryonic stem
- Genomic DNA fragments of Gab1 were isolated by screening a .lambda.DASHII mouse genomic library, (Stratagene, La Jolla Calif.), with a Gab1 cDNA fragment as a probe.
- the sequence of Gab1 is known and presented in a variety of databases, including Project Ensembl from The Wellcome Trust Sanger Institute.
- the Mouse Gab1 gene is listed herein as SEQ ID No.: 1.
- the cDNA probe is listed herein as SEQ ID No.: 2, and is generated from a partial sequence of SEQ ID No.: 1.
- a targeting construct was engineered using a triple-loxP construction system, wherein the genomic DNA fragments were cloned into the targeting vector as left, central and right arms.
- a targeting construct was engineered using a triple-loxP construction system, wherein the genomic DNA fragments were cloned into the targeting vector as left, central and right arms.
- Exon 3 codes for amino acids 124-198 of the Gab1 protein and deletion of this exon leads to a frame-shift mutation and to the introduction of a new stop codon immediately. Exon 3 nucleic acids are listed at SEQ ID No.: 3.
- the recombinant construct DNA is then linearized using NotI (NEB, Inc., Beverly Mass., Catalog No.: R0189S) and introduced into R1 ES cells using electroporation.
- ES cell colonies resistant to the Geneticin Antibiotic G418 (Sigma, St. Louis, Mo., Cat No.: G-9516) were screened for homologous recombination by PCR using a primer in the neo cassette and a primer outside of the right arm.
- the Gab1.sup.flox allele and the Gab1 knockout (Gab1 ⁇ ) allele can be distinguished by PCR analysis using primers A (SEQ ID No.: 4) and B (SEQ ID No.: 5) that produces DNA fragments at 670 by and 200 bp, respectively. Results were confirmed using Southern Blot analysis with a 5′ probe (Southern Blot techniques are well known in the art.
- FIG. 1 b See for example, Maniatis et al., Molecular Cloning: A Laboratory Manual (1989), 2nd Ed., Cold Spring Harbor, N.Y.) ( FIG. 1 b ). Briefly, genomic DNA was digested with ApaI or BamHI and hybridized to the .sup.32P-labelled 3′ probe or 5′ probe. Three properly targeted clones (F/+) show one 6 kb band for the Gab1.sup.flox allele and another 10 kb band for the wild-type allele. The lower panel of FIG. 1 b shows a 24 kb band for the wild-type allele and 12 kb for Gab1.sup.flox allele, detected by the 3′ probe upon ApaI digestion of genomic DNA.
- ES cells were then transiently transfected with a CMV-Cre construct (pBS185; Invitrogen Corp., Carlsbad, Calif.). Cells containing the CMV-cre construct were selected in fialuridine (FIAU)-containing medium against the TK-neo cassette. (FIAU, Moravek Biochemicals, Brea Calif., Cat. No. M-251.)
- FIAU fialuridine
- Surviving clones were further screened by PCR analysis using primers A and B (SEQ ID No.: 4 and SEQ ID No.: 5, respectively), described above, thereby allowing for isolation of ES cell clones with a loxP-floxed Gab1 allele (Gab1.sub.flox).
- the engineered ES cells were injected into C57BL/6 blastocysts and chimeric animals were obtained. Germline transmission of the Gab1.sub.flox allele was obtained from two independent ES cell clones isolated from the screen.
- the Gab1.sup.flox allele was generated in a 129/Sv background and mutant mice were crossed with wild-type C57BL/6 animals for 4 generations to acquire the C57BL/6 background.
- To generate liver-specific Gab1 knockout (LGKO) mice Gab1.sup.flox/+ mice were crossed with Albumin-Cre transgenic mice (C57BL/6-TgN (Alb-cre)21Mgn).
- LGKO liver-specific Gab1 knockout mice
- C57BL/6-TgN (Alb-cre)21Mgn Albumin-Cre transgenic mice
- LGKO mice (Gab1.sup.flox/flox:Alb-cre/+) were born with the expected Mendelian frequency, morphologically indistinguishable from their wild-type (WT) littermates. All animals were housed in virus-free facility on a 12 hr light/dark cycle and were fed with a standard mouse food. All protocols for animal use and euthanasia were approved by the institutional animal committee.
- Genotyping PCR used the following primers: Cre primers GCC TGC ATT ACC GGT CGA TGC AAC GA, (SEQ ID No.: 6) GTG GCA GAT GGC GCG GCA ACA CCA TT (SEQ ID No. 7) and Gab1.sup.Flox/wild-type primers: GGT GAA TCG ACG GGT GCT TGT GA, (SEQ ID No.: 8) CAG ATT GGC CTT GAA CTG GTA AG (SEQ ID No.: 9).
- the PCR program used was: 94° C.
- PCR analysis of the LGKO mice showed an efficient deletion of exon 3 in the liver but not other organs such as skeletal muscles, pancreas, brown and white adipose tissue, hypothalamus, pituitary and kidney. ( FIG. 1 c ).
- mice at age of 2 month were fasted for 16 hr and were anaesthetized intraperitoneally with Avertin (0.015 ml/g) (2,2,2 tribromoethanol, purchased at Aldrich Cat. No.: T4,840.2).
- Avertin 0.015 ml/g
- T4,840.2 tribromoethanol
- Either 5 U of human insulin (Humalin, Eli Lilly & Company) or 20 microliters saline solution was injected into the inferior vena cava. Liver and muscle tissue were harvested as indicated above, and quickly frozen in liquid nitrogen.
- Frozen liver and muscle samples were homogenized in a Dounce apparatus in Protein lysis buffer (50 mM Hepes pH7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EGTA, 100 mM NaF, 10 mM sodium pyrophosphate, 10 mM Na3VO4, 10 micrograms/ml leupeptin, 10 ug/ml aprotinin, 2 mM PMSF). After 30 min incubation on ice, tissue lysates were clarified by centrifugation at 37,000 g for 1 hr at 4° C. Protein concentration was determined using a kit from Bio-Rad (Bio-Rad Protein Assay, Hercules, Calif., Catalogue No.: 500-0001).
- lysates were separated on SDS-polyacrylamide gels, transferred to a nitrocellulose membrane, and blotted with primary antibodies as indicated. Specific signals were detected by enhanced chemiluminescence (ECL analysis kit; Amersham Corp.) following blotting with horseradish peroxidase-conjugated secondary antibodies.
- Antibody against Gab1 was produced by injection of rabbits with purified glutathione S-transferase fusion protein of Gab1 following standard procedures.
- Antibodies to phospho-Akt (serine 473), Akt, phospho-p44/42 Erk, Phospho-(Tyr) p85 of PI3K, phospho-IRS-1 (Ser612) were obtained from Cell Signaling Technologies (Beverly Mass.).
- Antibodies to p85.alpha., p110.alpha., IR.beta., Erk1/2 were obtained from Santa Cruz Biotechnology (Santa Cruz, Calif.).
- Anti-phosphotyrosine antibody was purchased from Upstate Biotechnology Inc. (Charlottesville, Va.).
- IRS-1 and IRS-2 antibodies were kindly provided by Joslin Diabetes Center, Boston, Mass., and are further available from Upstate—Cell Signaling Solutions (Charlottesville, Va., Catalog Nos.: 06-248 and 06-506). Those of skill in the art will readily prepare antibodies to an antigen using well known techniques (See e.g., Harlow, Ed, Lane, David, Antibodies: A Laboratory Manual, 1988, Cold Springs Harbor Press). Blots were scanned and signals were quantified using IMAGEQUANT.sup.TM. software. Statistical analysis of the data was performed using a two-tailed unpaired t-test, expressing values as mean ⁇ SEM.
- Gab1 protein was barely detectable in the liver of LGKO mice (Gab1.sup.flox/flox Alb-Cre/+), but Gab1 expression was not changed in the liver of Gab1.sup.+/+:+/+ (wt); Gab1.sup.+/+:Alb-Cre/+ (Cre/+); Gab1.sup.flox/flox:+/+ (F/F); Gab1. sup.flox/+:Alb-cre/+ (Cre/+, F/+) mice.
- GTT glucose tolerance test
- IP intra-peritoneal
- ITT Insulin tolerance tests
- a bolus of insulin (1 U insulin per kg of body weight), (Humulin, Eli Lilly and Company, Indianapolis, Ind. 46285).
- Blood glucose levels were measured at time point 0, 15, 30 and 60 minutes after intra-peritoneal injection of human insulin using Lifescan's One Touch system.
- Serum insulin levels were measured by ELISA, using rat insulin as a standard (Cat#: INSKR 020, Crystal Chem, Inc. Downers Grove, Ill. 60515). Serum triglyceride levels were measured by Animal Care Program, Diagnostic Laboratory, University of California, San Diego.
- insulin's ability to reduce circulating glucose levels was similar between the genotypes at both ages. Since the insulin tolerance test is a relatively crude technique for assessment of insulin stimulated glucose disposal, the more accurate glucose clamp technique was used to quantitatively assess overall in vivo insulin action, quantify the rates of glucose disposal and hepatic glucose production.
- each mouse was implanted with two catheters in the right jugular vein which were tunneled subcutaneously, exteriorized at the back of the neck, and encased in silastic tubing.
- animals were fasted for 6 hours and glucose turnover was measured in the basal state and during a hyperinsulinemic-euglycemic clamp.
- basal sampling approximately 90 min
- a constant infusion 5.micro.Ci/h
- [3-3H] D-glucose NN Life Science Products Inc.
- a second basal blood sample was taken for measurement of glucose concentration and tracer specific activity as previously described 28.
- regular human insulin (12 mU ⁇ kg-1 ⁇ min-1, Novolin R; Novo Nordisk Pharmaceutical Industries Inc.) combined with [3-3H] D-glucose (5.micro.Ci/h) was infused.
- Steady state was achieved by 80 minutes and held for the duration of the 120 minutes clamp.
- a final blood sample was taken for measurement of glucose turnover.
- Plasma glucose concentration was measured with a HemoCue glucose analyzer (Hemocue Inc., Lake Forrest, Calif. 92630).
- Circulating plasma human insulin following the clamp was measured using a radioimmunoassay kit (Linco Research, St. Charles, Mo. 63304, RIA Kit, Catalog No.: MENDO-75K). Plasma glucose specific activity was measured after deproteinization with barium hydroxide and zinc sulfate as previously described by our laboratory. Hepatic glucose production (HGP) and glucose disposal rate (GDR) were calculated at basal and during the 30-minute steady state portion of the glucose clamp. Tracer determined rates were quantified using the Steele equation for steady state conditions. Comparisons between the two groups were conducted using analysis variance (ANOVA), and values were presented as means ⁇ SEMs. Clamp techniques are well know in the art. (Miles, P.
- Glucose is converted to fat in the liver, and triglycerides are released in blood by the liver.
- the amount of fasting triglycerides was slightly lower for both the 2-month-old (14.8% reduction) and 1-year-old (22.7% reduction) knockout mice ( FIG. 3 h ).
- Gab1 deletion in the liver also changed hepatic lipid metabolism.
- Gab1 promotes the Erk pathway in attenuating insulin-elicited signals through the IRS signalling pathway.
- Gab1 deficiency in hepatocytes removes Gab1 mediated attenuation of IRS, resulting in increased basal and insulin-stimulated Akt/PKB activity.
- Akt/PKB kinase a critical enzyme in insulin signaling
- Tissue lysates were made from the liver at 0, 2 and 5 min after insulin administration, and muscle lysates were prepared at 0, 4 and 8 min following insulin injection ( FIG. 4 a ), and lysates were detected using immunoblot techniques as described hereinabove.
- Both basal and insulin-stimulated levels of p-Akt were higher in LGKO liver than that in wild-type, without a change in protein expression levels of Akt.
- elevated Akt activity was detected in the LGKO liver only, with no difference observed in skeletal muscle. Immunoblot and other techniques for measuring the level of protein in tissue samples are well known in the art.
- Inventors measured the tyrosine phosphorylation status of the beta subunit of insulin receptor (IR.beta.) and observed its normal activation in LGKO liver as well as in muscle ( FIGS. 4 b and 4 c ).
- the IR.beta. expression level was not changed either ( FIG. 5 ). Therefore, the increased Akt activity can not be attributed to a change in IR.beta. activation or expression but is rather caused by a downstream event.
- IRS-1 tyrosine phosphorylation was the most affected, with a 2.0 fold increase at the basal level and a 1.4 fold increase after insulin stimulation, whereas it was about 1.4 fold improved at both conditions for IRS-2.
- mice were injected via vena cava with a saline solution (control), insulin (5 U), EGF (100 ⁇ g), or peroxo-vanadate.
- Liver extracts were prepared 2 min after injection; immunoprecipitated with Gab1 antibody; and immunoblotted with antibodies against either phosphotyrosine (PY), Gab1, phospho-(Tyr) p85 PI3K (p-YXXM), or p85.
- Peroxo-vanadate solution was prepared following a procedure published previously (S. J. Ruff, K. Chen, S. Cohen, J Biol Chem 272, 1263-7 (Jan. 10, 1997)).
- Gab1 is the primary mediator for insulin-stimulated Erk activation, which leads to serine phosphorylation of IRS-1 and attenuation of its tyrosine phosphorylation. This, in turn, results in down-regulation of the IRS/PI3K/Akt pathway.
- This negative feedback loop in hepatocytes is a critical molecular mechanism for glucose homeostasis, as controlled by insulin ( FIG. 6 ).
- the negative regulatory role of Gab1 in glucose metabolism is connected with its positive effect in mediating cell mitogenesis via the Erk pathway.
- pharmaceutical interference of the Gab1 activity in insulin signaling not only reduces blood glucose levels but also may suppress unwanted mitogenic activities in the liver.
- Dysregulation of the glucose homeostasis pathway can lead to numerous disorders ranging from altered blood pressure to diabetes.
- Diabetes mellitus is the most common public health problem worldwide, affecting over 5% of the population in western countries. Ninety-five percent (95%) of the cases are classified as type II or non-insulin-dependent diabetes mellitus, which results from resistance to insulin activity (Kahn, B. B. & Rossetti, L. Nat Genet 20, 223-5 (1998), Taylor, S. I. Cell 97, 9-12 (1999)).
- search for negative regulators of the glucose homeostasis pathway is of particular interests in development of therapeutic strategies for related diseases.
- Gab1 presents as an attractive target for addressing these goals.
- the negative regulatory role of Gab1 in glucose homeostasis is connected with its positive effect in mediating cell mitogenesis via the Erk pathway.
- Disruption of the Gab1 activity in insulin signalling may not only reduce blood glucose level but also may suppress unwanted mitogenic activities in the liver, thereby preventing hepatic carcinogenesis.
- Inventors have uncovered a novel balancing mechanism for control of insulin signal strength in liver via the actions of Gab1.
- Inventors' discovery leads to a novel method for discovering new therapeutic modulators for treating type II diabetes mellitus, and other regulatory disorders of the glucose homeostasis pathway.
- Inventors' discovery also leads to a novel method for diagnosing the origin of disorders related to glucose homeostasis dysregulation, and developing specific treatments therefore.
- High Throughput Screening techniques are well known in the art and applicable to methods using Inventors' discovery.
- the number of different candidate compounds used to test in the methods of the invention will depend on the application of the method For example, one or a small number of candidate compounds can be advantageous in manual screening procedures, or when it is desired to compare efficacy among several predicted ligands, agonists or antagonists. However, it is generally understood that the larger the number of candidate compounds, the greater the likelihood of identifying a compound having the desired activity in a screening assay. Additionally, large numbers of compounds can be processed in high-throughput automated screening assays. Therefore, “one or more candidate compounds” can be, for example, 2 or more, such as 5, 10, 15, 20, 50 or 100 or more different compounds, such as greater than about 103, 105 or 107 different compounds, which can be assayed simultaneously or sequentially
- a first screening assay takes advantage of the methods and procedures described above.
- LGKO and WT mice are generated using the previously described procedures. Blood glucose levels, Glucose tolerance tests and Insulin tolerance tests are performed at time point 0, as described. The mice are then given a bolus of glucose.
- the control group comprises both WT mice and the LGKO mice, which receive the bolus of glucose alone.
- the test group comprises WT and the LGKO mice; however, the test group receives a bolus of glucose and one or more candidate compounds.
- a candidate compound can be a naturally occurring macromolecule, such as a polypeptide, amino acid, nucleic acid, carbohydrate, lipid, or any combination thereof.
- a candidate compound also can be a partially or completely synthetic derivative, analog or mimetic of such a macromolecule, or a small organic molecule prepared by combinatorial chemistry methods.
- Candidate compounds can be given concurrently with the bolus of glucose or at a time point before or after the administration of said bolus of glucose. The Blood glucose levels, Glucose tolerance tests and Insulin tolerance tests are again performed, this time at time points 15, 30, 60 and 120, as described.
- Measurements received from the control group establish baseline glucose levels, glucose tolerance and baseline insulin tolerance. As described above, there is a difference in the blood glucose levels and in glucose tolerance, but not insulin tolerance, between the WT and LGKO mice, thus the control group will establish data parameters for mice with functional Gab1 and with a knockout Gab1.
- the test group will receive a glucose bolus and one or more candidate compounds. Each candidate compound will be tested in WT and LGKO mice.
- Candidate compounds that modulate the glucose homeostasis pathway are useful in treating the conditions associated with dysregulation of said glucose homeostasis pathway. For example, LGKO mice receiving a candidate compound that increases blood glucose levels reveal an ideal candidate modulator for treating hypoglycemia. Similarly, WT mice receiving a candidate compound that decreases blood glucose levels reveal an ideal candidate modulator for treating hyperglycemia. Glucose tolerance modulators are also discovered using this screening method.
- test agents are screened to see if said test agent is capable of modulating Gab1 mediated Erk1/2 activity.
- test agents are screened to see if said test agent is capable of modulating Gab1 mediated Erk1/2 activity.
- Those of ordinary skill in the art will readily uncover this same information using a variety of methods; however, in this example hepatic cell lines containing the Gab1 mediated glucose homeostasis pathway are used.
- hepatic cells are plated in a multi-well cell culture plate containing 96 wells, 384 wells, 1594 or other commercially available well numbers, and are incubated according to well known procedure. Otherwise identical wells are then either exposed to one or more candidate compounds in a glucose solution (test wells) or are exposed to glucose solution alone (control wells).
- a candidate compound can be a naturally occurring macromolecule, such as a polypeptide, amino acid, nucleic acid, carbohydrate, lipid, or any combination thereof.
- a candidate compound also can be a partially or completely synthetic derivative, analog or mimetic of such a macromolecule, or a small organic molecule prepared by combinatorial chemistry methods.
- the wells are immediately and incrementally assayed for glucose concentration.
- the response of the test cell to a candidate compound is compared to the response (or lack of response) of the control cell to the same compound under substantially the same reaction conditions.
- Candidate compounds that reduce the level of glucose in the test well as compared to the control are considered to negatively modulate Gab1 mediated Erk1/2 activity, thereby leading to a hypoglycemic environment.
- candidate compounds that result in a higher level of glucose in the test well as compared to the control are considered to positively modulate Gab1 mediated Erk1/2 activity, thereby leading to a hyperglycemic environment.
- Candidate compounds shown to modulate Gab1 mediated Erk1/2 activity are useful in treating the conditions associated with dysregulation of the glucose homeostasis pathway.
- hepatic cell lines comprise either a wild type Gab1 or a Gab1 knockout.
- the assay is performed as is Screening Assay Two: cells are plated in wells; the wells are exposed to glucose alone (control well) or glucose and one or more candidate compounds (test wells); and subsequent glucose concentration data is acquired.
- control wells present data for the Gab1 mediated glucose homeostasis pathway wherein either Gab1 is functional or wherein Gab1 is knocked out.
- Candidate compounds that cause a decrease in glucose concentration in the wild type wells function to modulate the Gab1 mediated glucose homeostasis pathway in a manner similar to when Gab1 is knocked out. These modulators are useful for treating hyperglycemia.
- candidate compounds that cause an increase in glucose concentration in the LGKO wells function to modulate the Gab1 mediated glucose homeostasis pathway in a manner similar to when Gab1 is functionally present.
- candidate compounds are screened to determine whether said candidate compound is capable of modulating Gab1 wherein said screening method includes (a) contacting Gab1 under conditions suitable to promote MapK activation by insulin; (b) measuring the activity of insulin-stimulated MapK; (c) contacting Gab1 with a candidate compound; and (d) determining the ability of the candidate compound to modulate glucose homeostasis, where modulation of insulin-stimulated MapK activity indicates that the candidate compound is an effective compound that modulates glucose homeostasis.
- such a screening method can include a hepatic cell line comprising the Gab1 signaling pathway.
- the hepatocytes are plated in a cell culture well under suitable conditions.
- Such cell culture wells may be part of a multi-well plate having 96-wells, 384-wells or any number of wells commercially available.
- Those of skill in the art will readily adapt the current example to high throughput screening. Such applications are anticipated by the current disclosure.
- the wells are designated as either negative control (cell media only); positive control (cell media and insulin) or test wells type A (cell media, insulin and candidate compound) and test wells type B (cell media and candidate compound).
- the cells are incubated under suitable conditions along with negative control media, positive control media, type A media or type B media. Following incubation, the cells are lysed at the optimal time and the extracts are assayed for MapK (Erk1/2) activity using immunoblot techniques. An antibody specific for phospho serine 612 of IRS-1 is used to detect insulin mediated activity of Erk1/2 t.
- the phosphorylation of IRS-1 in the presence of a candidate compound is compared to the control wells.
- Data acquired from the control wells establishes the degree of Gab1 mediated glucose homeostasis pathway activity in the presence and absence of insulin.
- Data from the test wells can be compared to the control wells.
- Candidate compounds causing an increase or decrease in insulin mediated activity of Erk1/2, as compared to control wells, determined by relative levels of phosphorylation at Ser612 residue of IRS-1, are useful as modulators of the Gab1 mediated glucose homeostasis pathway.
- modulators that activate the Gab1 pathway in the absence of insulin are useful for treating insulin production and/or release mediated disorders, while those that act in the presence of insulin are useful for disorder occurring despite the presence of insulin.
- Modulators that increase IRS-1 phosphorylation are useful for treating hypoglycemia, while those that reduce IRS-1 phosphorylation are useful for treating hyperglycemia.
- the current invention is additionally useful in diagnosing whether a dysregulation of the glucose homeostasis pathway is related to the Gab1 signaling pathway. For example, using the technique described in Screening Assay Two, hepatic cells obtained from the liver biopsy of a patient suffering from a disorder related to glucose homeostasis dysregulation can be assayed.
- Biopsied hepatic cells are plated in a cell culture plate, which may be multi well containing 96 wells, 384 wells, 1594 wells or other commercially available well numbers, and are incubated according to well known procedure. Otherwise identical wells are then either exposed to Gab1 modulators in a glucose solution (test wells) or are exposed to glucose solution alone (control wells).
- Gab1 modulators as used in this Diagnostic Assay, are those that have been identified to restore glucose homeostasis in LGKO mice, or other Gab1 deficient systems.
- the wells are immediately and incrementally assayed for glucose concentration.
- the response of the test cell to the modulator is compared to the response in the control cell under substantially the same reaction conditions. If the Gab1 modulator causes a restoration of glucose homeostasis in said test cell, then the diagnosis and subsequent treatments can be tailored to treating a Gab1 deficiency.
- Methods of using the compounds and pharmaceutical compositions of the invention are also provided herein.
- the methods involve both in vitro and in vivo uses of the compounds and pharmaceutical compositions for altering preferred nuclear receptor activity, in a cell type specific fashion.
- the claimed methods involve the discovery and use of modulating compounds including agonists, antagonists, ligands, small molecules, peptides and nucleic acid molecules.
- an agent can be put in a pharmaceutically acceptable formulation, such as those described in Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Co., Easton, Pa. (1990), incorporated by reference herein, to generate a pharmaceutical composition useful for specific treatment of diseases and pathological conditions.
- Agents identified by the methods taught herein can be administered to a patient either by themselves, or in pharmaceutical compositions where it is mixed with suitable carriers or excipient(s).
- a therapeutically effective amount of agent or agents such as these is administered.
- a therapeutically effective dose refers to that amount of the agent resulting in amelioration of symptoms or a prolongation of survival in a patient.
- the agents also can be prepared as pharmaceutically acceptable salts.
- pharmaceutically acceptable salts include, but are not limited to acid addition salts such as those containing hydrochloride, sulfate, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate.
- Such salts can be derived using acids such as hydrochloric acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, and quinic acid.
- acids such as hydrochloric acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, and quinic acid.
- salts can be prepared by standard techniques. For example, the free base form of the agent is first dissolved in a suitable solvent such as an aqueous or aqueous-alcohol solution, containing the appropriate acid. The salt is then isolated by evaporating the solution. In another example, the salt is prepared by reacting the free base and acid in an organic solvent.
- a suitable solvent such as an aqueous or aqueous-alcohol solution
- Carriers or excipients can be used to facilitate administration of the agent, for example, to increase the solubility of the agent.
- carriers and excipients include calcium carbonate, calcium phosphate, various sugars or types of starch, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and physiologically compatible solvents.
- the compounds of the invention can be incorporated into liposomes (Gregoriadis, Liposome Technology, Vols. I to III, 2nd ed. (CRC Press, Boca Raton Fla. (1993)).
- Liposomes which consist of phospholipids or other lipids, are nontoxic, physiologically acceptable and metabolizable carriers that are relatively simple to make and administer.
- the therapeutic compound can be conjugated to a peptide that facilitates cell entry, such as penetratin (also known as Antennapedia peptide), other homeodomain sequences, or the HIV protein Tat.
- Toxicity and therapeutic efficacy of such agents can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population).
- the dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50.
- Agents which exhibit large therapeutic indices are preferred
- the data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in humans.
- the dosage of such agents lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity.
- the dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- the therapeutically effective dose can be estimated initially from cell culture assays.
- a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 as determined in cell culture (i.e., the concentration of the test agent which achieves a half-maximal disruption of the protein complex, or a half-maximal inhibition of the cellular level and/or activity of a complex component).
- IC50 as determined in cell culture
- levels in plasma may be measured, for example, by HPLC.
- the exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g. Fingl et al., in The Pharmacological Basis of Therapeutics, Ch. 1 p. 1 (1975)). It should be noted that the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity, or to organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity).
- the magnitude of an administrated dose in the management of the disorder of interest will vary with the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency, will also vary according to the age, body weight, and response of the individual patient. A program comparable to that discussed above may be used in veterinary medicine.
- Such agents may be formulated and administered systemically or locally.
- Techniques for formulation and administration may be found in Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Co., Easton, Pa. (1990). Suitable routes may include oral, rectal, transdermal, vaginal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections, just to name a few.
- the agents may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer.
- physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer.
- penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
- agents herein disclosed Use of pharmaceutically acceptable carriers to formulate the agents herein disclosed into dosages suitable for systemic administration is contemplated. With proper choice of carrier and suitable manufacturing practice, these agents, in particular, those formulated as solutions, may be administered parenterally, such as by intravenous injection.
- the agents can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration.
- Such carriers enable the agents of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
- Agents intended to be administered intracellularly may be administered using techniques well known to those of ordinary skill in the art. For example, such agents may be encapsulated into liposomes, then administered as described above. Liposomes are spherical lipid bilayers with aqueous interiors. All molecules present in an aqueous solution at the time of liposome formation are incorporated into the aqueous interior. The liposomal contents are both protected from the external microenvironment and, because liposomes fuse with cell membranes, are efficiently delivered into the cell cytoplasm. Additionally, due to their hydrophobicity, small organic molecules may be directly administered intracellularly.
- compositions suitable for use in the context of the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
- these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active agents into preparations which can be used pharmaceutically.
- the preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions.
- compositions contemplated by the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levitating, emulsifying, encapsulating, entrapping or lyophilizing processes.
- compositions for parenteral administration include aqueous solutions of the active agents in water-soluble form. Additionally, suspensions of the active agents may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the agents to allow for the preparation of highly concentrated solutions.
- compositions for oral use can be obtained by combining the active agents with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
- suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP).
- disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- Dragee cores are provided with suitable coatings.
- suitable coatings For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
- Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active agent doses.
- compositions which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
- the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
- the active agents may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
- stabilizers may be added.
- Some methods of delivery that may be used include:
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Food Science & Technology (AREA)
- Analytical Chemistry (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Physics & Mathematics (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Abstract
The invention is directed to the regulation of glucose homeostasis by modulating the activity of Grb2-associated binder 1 (Gab1) in hepatocytes. This invention also provides for a method for identifying compounds capable of modulating the glucose homeostasis regulatory activity of Gab1. In one aspect, the invention provides a method for identifying a compound that can effectively modulate glucose homeostasis wherein Gab1 mediated MapK activity indicates that the candidate compound is an effective compound that modulates glucose homeostasis. In another aspect, the invention provides a method for identifying a compound that can effectively modulate the glucose homeostasis regulating activity of Gab1 wherein MAPK is activated to phosphorylate Serine residue 612 of IRS-1, indicating that the candidate compound is an effective compound that modulates glucose homeostasis. In another aspect of the invention is provided a method for diagnosing Gab1 related disorders.
Description
- This application is a continuation of U.S. patent application Ser. No. 10/987,384, filed on Nov. 12, 2004, which claims benefit of priority under 35 U.S.C. 119(e) of U.S. Provisional Application No. 60/519,358, filed Nov. 12, 2003. The disclosures of the above referenced applications are herein incorporated by reference in their entireties.
- This work was supported by grants GM53660 and HL66208 from the National Institutes of Health. The government may have certain rights in this invention.
- The present application is being filed along with a Sequence Listing in electronic format. The Sequence Listing is provided as a file entitled BURNHAM031C1.TXT, created Sep. 10, 2010, which is 147 KB in size. The information in the electronic format of the Sequence Listing is incorporated herein by reference in its entirety.
- This invention relates to the field of molecular biology and molecular medicine, and more specifically to proteins involved in blood glucose homeostasis and diabetes.
- In humans, free glucose is present in the plasma and interstitial fluid at a concentration of approximately 80 mg per 100 ml. Blood glucose levels; however, are in a dynamic flux. Organs of the body remove the glucose from the blood for metabolic energy, while food intake loads glucose into the blood system. Under normal conditions, the body maintains a balance of blood glucose by absorbing excess glucose into many tissues.
- A rise in blood glucose is normally followed by a rise in blood insulin. Insulin secretion is stimulated by many events associated with glucose intake. Primarily, insulin is secreted by the pancreas. High glucose concentration in the vicinity of the .beta.cells of the pancreas is sensed by the glucose transporter GLUT-2 and is carried into the cells. The glucose is modified and begins a signal transduction cascade that results in insulin exocytosis.
- Rising concentrations of insulin in the blood have an effect on three main tissues—liver, muscle and adipose tissue. Liver tissues play a central role in glucose homeostasis primarily orchestrated by insulin (Saltiel, A. R. & Kahn, C. R. Nature 414: 799-806 (2001), Michael, M. D. et al. Mol Cell 6: 87-97 (2000)), although it is not well understood how the insulin-elicited signals are tightly controlled in hepatocytes.
- In general, insulin activates a four-subunit transmembrane receptor (insulin receptor) expressed on the surface of these tissue types. The activated insulin receptor phosphorylates and recruits different substrate adaptors such as the Insulin Receptor Substrate (IRS) family of proteins. IRS-1 and IRS-2 proteins are known to be positively required for relay of signals emanating from insulin receptor (Araki, E. et al. Nature 372: 186-90 (1994), Tamemoto, H. et al. Nature 372: 182-6 (1994), Withers, D. J. et al. Nature 391: 900-4 (1998)).
- Tyrosine phosphorylated IRS displays binding sites for numerous signaling partners. Among them, PI3K has a role in insulin function mainly characterized by the activation of the Akt/PKB and the PKC.zeta. cascades. These cascades are associated with glucagon synthesis and with glucose uptake. Glucose uptake is mediated by the translocation of glucose transport vesicles to the plasma membrane, which is regulated by numerous signal cascades including those discussed.
- Grb2-associated binder 1 (Gab1) is part of a family of adaptor proteins recruited by a wide variety of receptor tyrosine Kinases, such as the insulin receptor. Upon stimulation of the receptor by its cognate ligand, Gab is recruited to the plasma membrane, undergoes phosphorylation and functions as a multi protein assembly center Gab1 shares structural and functional homology with the IRS family of proteins, possessing a PH domain at the N-terminus, multiple tyrosine phosphorylation sites and proline-rich motifs for entertaining SH2- and SH3-containing proteins (Holgado-Madruga, M., et al. Nature 379: 560-4 (1996), Gu, H. & Neel, B. G Trends Cell Biol 13: 122-30 (2003)). Homozygous Gab1 mutant mice are embryonic-lethal with the phenotype revealing an essential role of Gab1 in promoting signals from epidermal growth factor (EGF) and hepatocyte growth factor (HGF), etc (Sachs, M. et al. J Cell Biol 150: 1375-84. (2000), Itoh, M. et al. Mol Cell Biol 20: 3695-704 (2000)).
- The insulin signalling pathway is critical for the regulation of intracellular and blood glucose levels (glucose homeostasis), and dysregulation of glucose homeostasis is indicated in numerous disorders. For example, diabetes mellitus is a group of diseases characterized by high levels of blood glucose resulting from defects in insulin production, insulin action, or both. There are two main forms of diabetes;
type 1 andtype 2.Type 1 patients are unable to produce insulin, and thus must receive exogenous insulin to survive. On the other hand,type 2 patients have at least partially preserved insulin production, but often are insulin resistant. Insulin resistance is caused by defects that may arise at the insulin receptor or post-insulin receptor levels. Post-insulin receptor defects often involve signal transduction proteins. - For the year 2003, the Center for Disease Control estimates that 17 million Americans have some type of diabetes, with an increasing prevalence during the last decade resulting in an incidence of about 1 million new cases per year. The prevalence and incidence of diabetes is even higher world wide, making diabetes a global health problem. Diabetes is the sixth leading cause of death in the United States.
- The primary treatment for diabetes is the delivery of exogenous insulin via pumps and/or injection. Total annual costs for treating diabetes is $132 billion, with $92 billion attributed to direct medical costs.
- Thus, there exists in the art a need to develop novel treatments for managing glucose homeostasis and blood glucose levels. There also exists in the art, a need to prevent the dysregulation of glucose homeostasis and blood glucose levels. Thus, there is a need in the art to better understand the insulin signaling pathway and Gab1.
- In one embodiment, a method of identifying a modulator of Gab1 includes providing a first group comprising cells that express Gab1 protein and a second group comprising cells modified to lack Gab1 protein expression; contacting the first group and second group with a candidate agent; comparing the extracellular glucose concentration of the first and second groups after contact with the candidate agent to a baseline value indicated by the difference in extracellular glucose concentration between the first and second groups without contact with the candidate agent; and identifying the candidate agent as a modulator of Gab1 if a change in glucose concentration between the first and second groups is found after contact with the candidate agent compared to the baseline value.
- In one aspect, the cells of the first and second groups comprise mammalian cells. In the same aspect, the cells of the first and second groups comprise murine cells. In the same aspect, the cells modified to lack Gab1 protein expression are from a transgenic mouse whose genome comprises a homozygous disruption of the endogenous Gab1 gene. In another aspect, the cells of the first and second groups are from the same organ type. In the same aspect, the organ type is liver.
- In a further aspect, the providing and the contacting are performed in vitro. In an additional aspect, the providing and the contacting are performed in vivo. In the same aspect, the first and second groups are mice. In the same aspect, the second group is a transgenic mouse whose genome comprises a homozygous disruption of the endogenous Gab1 gene. In the same aspect, the method further includes administering a known amount of glucose to the mice. In the same aspect, the extracellular glucose concentration is measured as plasma glucose levels.
- In a further aspect, the candidate agent is identified as a positive modulator of Gab1 if the change in glucose concentration is an increase. In yet an additional aspect, the candidate agent is identified as a negative modulator of Gab1 if the change in glucose concentration is a decrease.
- In another embodiment, a transgenic mouse is provided whose genome includes a homozygous disruption of the endogenous Gab1 gene, wherein the disruption results in the functional inactivation of the Gab1 gene, and wherein the mouse exhibits hypoglycemia relative to a mouse whose genome comprises the functional endogenous Gab1 gene. In one aspect, the homozygous disruption is specifically in the hepatic cells of the mouse. In another aspect, the disruption in the Gab1 gene is a deletion of SEQ ID NO: 3. In the same aspect, the Gab1 gene is replaced with a replacement gene. In the same aspect, the replacement gene includes a neomycin resistance gene In the same aspect, the replacement gene further includes a thymidine kinase gene.
-
FIG. 1 a: Generation of liver-specific Gab1 knockout mice: the targeting strategy. Genomic DNA fragments were cloned into the targeting vector as left, central and right arms. Three loxP sequences were marked by a black triangle (negative: HSV-TK; positive: PGK-NEO). Another negative selection marker, PGK-DT, was put outside of the right arm. The numbered boxes represent exons in the Gab1 gene. TK: thymidine kinase; NEO: neomycin; DT: diphtheria toxin. -
FIG. 1 b: Southern blot analysis. In the upper panel, genomic DNA was digested with BamHI and hybridized to the 32P-labelled 5′ probe. Three properly targeted ES cell clones flox/+ (F/+) showed a 6 kb band for the Gab1flox allele and a 10 kb band for the wild-type allele. The lower panel shows a 24 kb band for the wt allele and a 12 kb band for Gab1 fox allele, detected by the 3′ probe upon ApaI digestion of genomic DNA. -
FIG. 1 c: PCR with A and B primers on DNA extracted from a Gab1flox/flox mouse (+/+; F/F) and a LGKO mouse. The Gab1flox allele produces a 630 by fragment and the Gab1-allele produces a 150 by band. Deletion of the loxP-floxed sequences was detected only in the liver (L), but not in the tail (T), skeletal muscle (M), pancreas (P), brown adipose tissue (Ba), white adipose tissue (Wa), hypothalamus (H), pituitary gland (Pi), and kidney (K). -
FIG. 1 d: Immunoblot analysis of Gab1 protein expression in the liver, skeletal muscle, brain and white adipose tissue (Wa) isolated from mice of different genotypes: wild-type (WT), Albumin-Cre/+ (Cre/+), Gab1flox/flox (F/F), Alb-cre/+: Gab1flox/+ (Cre/+, F/+), and LGKO. Gab1 protein was barely detectable in the liver of LGKO mice. -
FIG. 1 e: Immunoblot analysis of Gab1 expression in liver and skeletal muscle of control (Ctl, Gab1flox/flox) and LGKO mice at the age of 2-month and 1-year, respectively. -
FIGS. 2 a and 2 b: Body weights of LGKO mice. Solid bars are for the control and open bars for LGKO mice. No statistically significant difference was observed between the two groups using the Student's t test analysis. Values are the means±SEM. (FIG. 2 a) Fed body weight of control and LGKO mice at the indicated ages and sex, N=19-24 for 2-month-old groups, N=6-25 for 6-month-old groups, N=7 to 19 for 1-year-old groups. (FIG. 2 b) Fasting body weight of control and LGKO mice at the indicated ages, N=9-14 for 2-month-old groups, N=5-22 for 6-month-old groups, N=7 for each 1-year-old group. M: Male; F: Female. -
FIG. 3 a. Metabolic changes of LGKO mice. Blood glucose levels were measured on randomly-fed (Fed) or 16-hr fasted (Fast) male (M) or female (F) mice; N=8 to 39 for each group. Serum insulin levels were measured on fed and fasted male mice; N=10 to 13 for each group. *P<0.05; **P<0.01; ***P<0.001 for control versus LGKO. Values are the means±SEMs. -
FIG. 3 b. Metabolic changes of LGKO mice. Blood glucose and serum insulin during glucose tolerance test performed on 16-hr-fasted male mice; N=5 to 8 for each group. *P<0.05; **P<0.01; ***P<0.001 for control versus LGKO. Values are the means±SEMs. -
FIG. 3 c. Metabolic changes of LGKO mice. Blood glucose level during insulin tolerance test performed on randomly-fed male animals; N=6 to 10 per group. *P<0.05; **P<0.01; ***P<0.001 for control versus LGKO. Values are the means±SEMs. -
FIG. 3 d: In vivo insulin sensitivity measured by Glucose infusion rate. One-year-old male mice were used, N=8. *P<0.05; **P<0.01 for control versus LGKO. Values are the means±SEMs. -
FIG. 3 e: In vivo insulin sensitivity measured by IS-GDR at the infusion rate of 12 mU/kg/min. One-year-old male mice were used, N=8. *P<0.05; **P<0.01 for control versus LGKO. Values are the means±SEMs. -
FIG. 3 f: In vivo insulin sensitivity measured by basal (bas.) and clamped (cl.) hepatic glucose productions (HGP). One-year-old male mice were used, N=8. *P<0.05; **P<0.01 for control versus LGKO. Values are the means±SEMs. -
FIG. 3 g: In vivo insulin sensitivity measured by insulin suppression of HGP, as determined by euglycemic, hyperinsulinemic clamp analyses. One-year-old male mice were used, N=8. *P<0.05; **P<0.01 for control versus LGKO. Values are the means±SEMs. -
FIG. 3 h: Serum triglyceride levels were measured for 16 hr-fasted mice (N=8, for 2-month-old mice; N=12-13 for 1-year-old animals). Solid bars represent the control mice and open bars and squares represent the LGKO mice. *P<0.05; **P<0.01; ***P<0.001 for control versus LGKO, Student's t tests. Values are the mean±SEM. -
FIG. 4 a: Biochemical analysis of insulin signalling in LGKO mice. The phosphorylation levels of Akt at Ser473 (p-Akt) were quantified against Akt proteins amounts at different time-points in the liver and muscle. Shown are statistical data collected from 3-4 mice, by setting the value of the control at 2 min to 100, as well as a representative immunoblot. *P<0.05; **P<0.01;***P<0.001 for control versus LGKO. Values are the means±SEMs. -
FIG. 4 b: Insulin-induced tyrosine phosphorylation of IR.beta. in LGKO liver. Left panel is the statistical data of 3-4 experiments using different mice each time, by setting the control value at 2 min to 100. Right panel is a representative immunoblot result. Tyrosine phosphorylation of IR.beta. (PY-IR), normalized against IR.beta. level (IR), in the liver at 0, 2 or 5 min after insulin treatment (N=4). Relative tyrosine phosphorylation of IR.beta. (PY-IR), in skeletal muscle at 0, 4, 8 min of insulin treatment (N=3). Solid bars represent the Control (Ctl) mice and open bars LGKO mice. No statistical significances were found between the two groups using the Student's t test. Values are the means±SEMs. -
FIG. 4 c: Biochemical analysis of insulin signalling in LGKO mice. Upper graph: relative PY levels of IRS-1, -2, in the liver at 0 and 2 min for insulin treatment (N=3). Lower graph: relative amounts of p85.alpha. binding to IRS-1 & -2, in the liver at 0, 2 min of insulin treatment (N=2 to 3). *P<0.05; **P<0.01; ***P<0.001 for control versus LGKO. Values are the means±SEMs. -
FIG. 4 d: Deletion of Gab1 leads to enhanced insulin signalling through IRS-1, -2 in hepatocytes. Mice were injected with 5 U insulin (Ins) (+) or saline (−) as a control via vena cava and liver extracts were prepared 2 min after injection. IRS-1 (left panel) or IRS-2 (right panel) were immunoprecipitated from liver lysates with specific antibodies and immunoblotted with antibodies against p85.alpha. subunit of PI3K, phosphotyrosine or against IRS-1, IRS-2 as a loading control. -
FIG. 4 e: Biochemical analysis of insulin signalling in LGKO mice. Tyrosine phosphorylation of Gab1 in the liver were measured 2 min after vena cava injection with 5 U insulin (Ins) (+) or saline (−). Two mice were included in each group. *P<0.05; **P<0.01; ***P<0.001 for control versus LGKO. Values are the means±SEMs. -
FIG. 4 f: High levels of Gab1 tyrosine phosphorylation in hepatocytes induced by EGF or peroxovanadate. Tyrosine phosphorylation of Gab1 in the liver was measured 2 min after vena cava injection with EGF or peroxovanadate. Gab1 was immunoprecipitated from liver lysates with Gab1 antibody and immunoblotted with antibodies against phosphotyrosine or Gab1 as a loading control. -
FIG. 4 g: Biochemical analysis of insulin signalling in LGKO mice. Gab1 phosphorylation on the p-YXXM motifs and its association with p85.alpha. in response to saline solution, insulin (ins), EGF, or peroxovanadate. *P<0.05; **P<0.01; *P<0.001 for control versus LGKO. Values are the means±SEMs. -
FIG. 4 h: Biochemical analysis of insulin signalling in LGKO mice. Insulin-induced p-Erk1/2 and p-IRS-1S612 were shown together with Erk2 and IRS-1 blots as loading controls. *P<0.05; **P<0.01; ***P<0.001 for control versus LGKO. Values are the means±SEMs. -
FIG. 4 i: Biochemical analysis of insulin signalling in LGKO mice. Inhibition of insulin-induced p-Erk1/2 and p-IRS-1S612 by PD98059 MEK inhibitor (left) or U0126 MEK inhibitor (right). *P<0.05; **P<0.01; ***P<0.001 for control versus LGKO. Values are the means±SEMs. -
FIG. 5 : Normal expression levels of proteins involved in insulin signaling. Immunoblot analysis was performed with lysates from liver or skeletal muscle of control and LGKO mice. Liver and muscle extracts were prepared after saline (−) or insulin (Ins) stimulation for 2 and 4 min, respectively (+). Deletion of Gab1 in the liver did not affect the hepatic expression of IRS-1, IRS-2, p85.alpha., Shp-2 or IR.beta. -
FIG. 6 : Inventors model for Gab1 activity (a negative feedback mechanism) in insulin signaling in the liver through the insulin mediated Gab1 protein signaling pathway. Gab1 promotes activation of MapK (Erk), leading to the phosphorylation of the Ser612 residue on IRS-1 and suppressing tyrosine phosphorylation on IRS-1. This, in turn, attenuates insulin-initiated signals flowing through IRS-1/PI3K/Akt pathway. - Definitions Used Herein:
- The term “site-specific recombination,” refers to DNA transfer from a donor DNA or vector to an acceptor DNA or vector.
- The term “lox sequence” refers to a nucleotide sequence which undergoes recombination (e.g., DNA cross-over and exchange) when catalyzed by a recombinase, such as Cre, Flp or another member of the Int family of recombinases (Argos et al. (1986) EMBO J. 5: 433). Suitable lox sequences include, for example, the lox sequences recognized by Cre recombinase, and the frt sequences recognized by Flp recombinase.
- The term “recombinase” refers to any recombinase capable of catalyzing a site-specific recombination at a lox site. Suitable recombinases include, for example, Cre recombinase (Sauer et al. (1993) Methods in Enzymology 225: 898) and Flp recombinase (Buchholz et al. (1996) Nucl. Acids Res. 24:4256-4262; Buchholz et al. (1998) Nat. Biotechnol. 16:657-662).
- The terms “acceptor DNA” and “acceptor vector,” are used interchangeably herein and refer to any DNA or vector which, preferably, is capable of integrating into the genome of a cell. For example, the acceptor DNA or vector can be of viral origin, such as a retroviral vector or adeno-associated vector. Generally, the acceptor DNA or vector contains an exchange cassette (i.e., DNA which is replaced by DNA from the donor vector) and can also, optionally, contain a selectable (e.g., negative) marker gene.
- The terms “donor DNA” and “donor vector” are used interchangeably herein and refer to any DNA or vector (e.g., circular plasmid DNA) containing DNA which is transferred to the acceptor DNA or vector via a recombinase-mediated exchange reaction. Generally, the donor DNA or vector comprises plasmid DNA and, optionally, also can contain a selectable (e.g., positive) marker gene.
- Methods for preparing large libraries of compounds, including simple or complex organic molecules, metal-containing compounds, carbohydrates, peptides, proteins, peptidomimetics, glycoproteins, lipoproteins, nucleic acids, antibodies, and the like, are well known in the art and are described, for example, in Huse, U.S. Pat. No. 5,264,563; Francis et al., Curr. Opin. Chem. Biol. 2:422-428 (1998); Tietze et al., Curr. Biol., 2:363-371 (1998); Sofia, Mol. Divers. 3:75-94 (1998); Eichler et al., Med. Res. Rev. 15:481-496 (1995); and the like. Libraries containing large numbers of natural and synthetic compounds also can be obtained from commercial sources.
- The number of different candidate compounds to test in the methods of the invention will depend on the application of the method. For example, one or a small number of candidate compounds can be advantageous in manual screening procedures, or when it is desired to compare efficacy among several predicted ligands, agonists or antagonists. However, it is generally understood that the larger the number of candidate compounds, the greater the likelihood of identifying a compound having the desired activity in a screening assay. Additionally, large numbers of compounds can be processed in high-throughput automated screening assays. Therefore, “one or more candidate compounds” can be, for example, 2 or more, such as 5, 10, 15, 20, 50 or 100 or more different compounds, such as greater than about 103, 105 or 107 different compounds, which can be assayed simultaneously or sequentially.
- The present invention relates to the discovery that Gab1 protein is a negative regulator of the glucose homeostasis pathway. In the current discovery, Inventors have shown that when Gab1 is knocked-out in the liver in mammals, the mammal will display hypoglycemia and enhanced glucose tolerance. Inventors' showing leads to the discovery that Gab1 promotes action in the MapK (Erk) pathway, which in turn downregulates the IRS pathway, leading to hypoglycemia and enhanced glucose tolerance.
- To determine how Gab1 functions in glucose homeostasis, Inventors generated a mouse model in which the Gab1 gene was specifically disrupted in the liver. Methods for generating a knock out mouse are generally well known in the art. (Brown, T. A., Gene Cloning and DNA Analysis, Ed. 4, Blackwell Science Press (2001)). Liver-specific Gab1 knockout (LGKO) mice were created to possess a conditional Gab1 knockout allele, a loxp-foxed allele of Gab1 (Gab1.sup.flox). Two loxP sites were inserted into
introns flanking exon 3 of the Gab1 gene using homologous recombination in embryonic stem (ES) cells (FIG. 1 a). Methods and techniques for achieving efficient and stable site-specific DNA recombination using a recombinase/lox system, such as the Cre/lox system or the Flp/frt system, are well known in the art. - Genomic DNA fragments of Gab1 were isolated by screening a .lambda.DASHII mouse genomic library, (Stratagene, La Jolla Calif.), with a Gab1 cDNA fragment as a probe. The sequence of Gab1 is known and presented in a variety of databases, including Project Ensembl from The Wellcome Trust Sanger Institute. The Mouse Gab1 gene is listed herein as SEQ ID No.: 1. Similarly, the cDNA probe is listed herein as SEQ ID No.: 2, and is generated from a partial sequence of SEQ ID No.: 1. Based on the restriction map, (determined using the Flash Non-Radioactive Gene Mapping Kit, Stratagene, La Jolla Calif.), and partial sequencing of Gab1 genomic DNA fragments, a targeting construct was engineered using a triple-loxP construction system, wherein the genomic DNA fragments were cloned into the targeting vector as left, central and right arms. (See e.g., Jr-Wen Shui and Tse-Hua Tan, Genesis, 39:3, p217. See also, Wang, Xinhe, et al., PNAS, 99:26, 16881; and Zhu, Y. J. et al. Journal of Bio. Chem. 278 (3): 1986-1990; and Gainetdinov, R. R. et al., Neuron, 24, 1029 (1999); and Gainetdinov, R. R. et al., Neuron, 38, 291 (2003)). The Gab1 gene and the target construct are homologously recombined, resulting in three loxP sequences flanking the central arm and the negative/positive selection marker genes (negative: HSV-TK; positive: PGK-NEO), allowing for cell selection. (Dr. R. T. Premont (Duke University, Durham, N.C.) provided the triple-loxp vectors. See also Gainetdinov, R. R. et al., Neuron, 24, 1029 (1999); and Gainetdinov, R. R. et al., Neuron, 38, 291 (2003)). Another negative selection marker, PGK-DT, was put outside of the right arm.
Exon 3 codes for amino acids 124-198 of the Gab1 protein and deletion of this exon leads to a frame-shift mutation and to the introduction of a new stop codon immediately.Exon 3 nucleic acids are listed at SEQ ID No.: 3. The recombinant construct DNA is then linearized using NotI (NEB, Inc., Beverly Mass., Catalog No.: R0189S) and introduced into R1 ES cells using electroporation. - ES cell colonies resistant to the Geneticin Antibiotic G418 (Sigma, St. Louis, Mo., Cat No.: G-9516) were screened for homologous recombination by PCR using a primer in the neo cassette and a primer outside of the right arm. The Gab1.sup.flox allele and the Gab1 knockout (Gab1−) allele can be distinguished by PCR analysis using primers A (SEQ ID No.: 4) and B (SEQ ID No.: 5) that produces DNA fragments at 670 by and 200 bp, respectively. Results were confirmed using Southern Blot analysis with a 5′ probe (Southern Blot techniques are well known in the art. See for example, Maniatis et al., Molecular Cloning: A Laboratory Manual (1989), 2nd Ed., Cold Spring Harbor, N.Y.) (
FIG. 1 b). Briefly, genomic DNA was digested with ApaI or BamHI and hybridized to the .sup.32P-labelled 3′ probe or 5′ probe. Three properly targeted clones (F/+) show one 6 kb band for the Gab1.sup.flox allele and another 10 kb band for the wild-type allele. The lower panel ofFIG. 1 b shows a 24 kb band for the wild-type allele and 12 kb for Gab1.sup.flox allele, detected by the 3′ probe upon ApaI digestion of genomic DNA. Gene Targeting techniques are well known to those of ordinary skill in the art, and are described in the literature. (See e.g., Joyner, A., Gene Targeting: A Practical Approach, The Practical Approach Series, edited by B. D. Hames, Oxford University Press 2.sup.nd Ed., Oxford 1999.) - ES cells were then transiently transfected with a CMV-Cre construct (pBS185; Invitrogen Corp., Carlsbad, Calif.). Cells containing the CMV-cre construct were selected in fialuridine (FIAU)-containing medium against the TK-neo cassette. (FIAU, Moravek Biochemicals, Brea Calif., Cat. No. M-251.) Surviving clones were further screened by PCR analysis using primers A and B (SEQ ID No.: 4 and SEQ ID No.: 5, respectively), described above, thereby allowing for isolation of ES cell clones with a loxP-floxed Gab1 allele (Gab1.sub.flox). The engineered ES cells were injected into C57BL/6 blastocysts and chimeric animals were obtained. Germline transmission of the Gab1.sub.flox allele was obtained from two independent ES cell clones isolated from the screen.
- Generation of liver-specific Gab1 knockout (LGKO) mice:
- The Gab1.sup.flox allele was generated in a 129/Sv background and mutant mice were crossed with wild-type C57BL/6 animals for 4 generations to acquire the C57BL/6 background. To generate liver-specific Gab1 knockout (LGKO) mice, Gab1.sup.flox/+ mice were crossed with Albumin-Cre transgenic mice (C57BL/6-TgN (Alb-cre)21Mgn). (See e.g., Michael, et al. Mol Cell 6: 87-97 (2000); and Postic et al., J Biol Chem 274, 305-15 (1999)). LGKO mice (Gab1.sup.flox/flox:Alb-cre/+) were born with the expected Mendelian frequency, morphologically indistinguishable from their wild-type (WT) littermates. All animals were housed in virus-free facility on a 12 hr light/dark cycle and were fed with a standard mouse food. All protocols for animal use and euthanasia were approved by the institutional animal committee.
- To determine the efficiency of
exon 3 deletion in the bred mice, PCR analysis was performed on genomic DNA extracted from the tails and liver of weaned mice. Genotyping PCR used the following primers: Cre primers GCC TGC ATT ACC GGT CGA TGC AAC GA, (SEQ ID No.: 6) GTG GCA GAT GGC GCG GCA ACA CCA TT (SEQ ID No. 7) and Gab1.sup.Flox/wild-type primers: GGT GAA TCG ACG GGT GCT TGT GA, (SEQ ID No.: 8) CAG ATT GGC CTT GAA CTG GTA AG (SEQ ID No.: 9). The PCR program used was: 94° C. for 5 min; 39 cycles at 94° C. for 30 s, 58° C. for 30 s, 72° C. for 45 s; 72° C. for 5 min. PCR analysis of the LGKO mice showed an efficient deletion ofexon 3 in the liver but not other organs such as skeletal muscles, pancreas, brown and white adipose tissue, hypothalamus, pituitary and kidney. (FIG. 1 c). - The efficiency of Gab1 deletion in LGKO hepatocytes was further demonstrated by immunoblot analysis.
- Male mice at age of 2 month were fasted for 16 hr and were anaesthetized intraperitoneally with Avertin (0.015 ml/g) (2,2,2 tribromoethanol, purchased at Aldrich Cat. No.: T4,840.2). Either 5 U of human insulin (Humalin, Eli Lilly & Company) or 20 microliters saline solution was injected into the inferior vena cava. Liver and muscle tissue were harvested as indicated above, and quickly frozen in liquid nitrogen. Frozen liver and muscle samples were homogenized in a Dounce apparatus in Protein lysis buffer (50 mM Hepes pH7.5, 150 mM NaCl, 10% glycerol, 1% Triton X-100, 1 mM EGTA, 100 mM NaF, 10 mM sodium pyrophosphate, 10 mM Na3VO4, 10 micrograms/ml leupeptin, 10 ug/ml aprotinin, 2 mM PMSF). After 30 min incubation on ice, tissue lysates were clarified by centrifugation at 37,000 g for 1 hr at 4° C. Protein concentration was determined using a kit from Bio-Rad (Bio-Rad Protein Assay, Hercules, Calif., Catalogue No.: 500-0001).
- For immunoprecipitation, 1.5 mg of total protein was incubated with 4-5 μl antibody for 2-4 hr at 4° C. and the mixture was further incubated for 2-4 hr at 4° C. with protein A/G plus agarose (Santa-Cruz Biotechnology, Santa Cruz, Calif., Cat No.: sc-2003). The bead-bound complex was washed three times with cold HNTG buffer (20 mM Hepes, pH7.5, 150 mM NaCl, 10% glycerol, 0.1% Triton X-100) and resuspended in 10 μl SDS sample buffer. For immunoblot analysis, lysates were separated on SDS-polyacrylamide gels, transferred to a nitrocellulose membrane, and blotted with primary antibodies as indicated. Specific signals were detected by enhanced chemiluminescence (ECL analysis kit; Amersham Corp.) following blotting with horseradish peroxidase-conjugated secondary antibodies. Antibody against Gab1 was produced by injection of rabbits with purified glutathione S-transferase fusion protein of Gab1 following standard procedures. Antibodies to phospho-Akt (serine 473), Akt, phospho-p44/42 Erk, Phospho-(Tyr) p85 of PI3K, phospho-IRS-1 (Ser612) were obtained from Cell Signaling Technologies (Beverly Mass.). Antibodies to p85.alpha., p110.alpha., IR.beta., Erk1/2 were obtained from Santa Cruz Biotechnology (Santa Cruz, Calif.). Anti-phosphotyrosine antibody was purchased from Upstate Biotechnology Inc. (Charlottesville, Va.). IRS-1 and IRS-2 antibodies were kindly provided by Joslin Diabetes Center, Boston, Mass., and are further available from Upstate—Cell Signaling Solutions (Charlottesville, Va., Catalog Nos.: 06-248 and 06-506). Those of skill in the art will readily prepare antibodies to an antigen using well known techniques (See e.g., Harlow, Ed, Lane, David, Antibodies: A Laboratory Manual, 1988, Cold Springs Harbor Press). Blots were scanned and signals were quantified using IMAGEQUANT.sup.™. software. Statistical analysis of the data was performed using a two-tailed unpaired t-test, expressing values as mean±SEM.
- As seen in
FIG. 1 d, the efficiency of Gab1 deletion was higher than 90% in LGKO liver, but Gab1 expression was not changed in skeletal muscle, brain or white adipose tissue. Gab1 protein was barely detectable in the liver of LGKO mice (Gab1.sup.flox/flox Alb-Cre/+), but Gab1 expression was not changed in the liver of Gab1.sup.+/+:+/+ (wt); Gab1.sup.+/+:Alb-Cre/+ (Cre/+); Gab1.sup.flox/flox:+/+ (F/F); Gab1. sup.flox/+:Alb-cre/+ (Cre/+, F/+) mice. Stable deletion of Gab1 was detected in young adult mice (2 months) as well as in aged 1-year old mice (FIG. 1 e). Deletion of Gab1; however, did not affect normal development and morphology of the liver. The ratio of liver versus body weight of mutant mice was normal (WT: 5.21±0.22%, N=6; LGKO: 5.23±0.13%, N=9). The body weight for mutant mice was also similar to the wild-type over a one-year period in both fed and fasted mice. (FIGS. 2 a and 2 b). - Glucose Homeostasis and LGKO Mice:
- To determine the effects of the Gab1 knockout on glucose homeostasis a series of metabolic and biochemical studies were performed.
- Blood glucose levels of both WT and LGKO mice were measured using whole venous blood and an automatic glucose monitor (e.g., One Touch Basic, Lifescan, Milpitas, Calif.). Surprisingly, the results of these studies revealed that LGKO animals are hypoglycaemic under both fed and fasted status when blood glucose levels are measured on sex- and age-matched mice (
FIG. 3 a). Selective deletion of hepatic Gab1 led to reduced blood glucose levels, ranged from 9.1 to 28.9%, in comparison between both fed and fasted states for gender- and age-matched mice (FIG. 3 a). For example, in comparison to control mice, the blood glucose concentrations in fasted male LGKO mice at the age of 2-month and 1-year were reduced by 19% (P=0.006) and 28.9% (P=0.009), respectively. Significant decrease of blood glucose levels was also detected in fed female LGKO animals (FIG. 3 a). Consistently, serum insulin levels in fed and fasted LGKO male mice were significantly lower than control littermates when measured at 2-month (Fed: P=0.0192; Fasted: P=0.0275) or 1-year (Fed: P=0.0356; Fasted: P=0.0171) (FIG. 3 a). This result strongly suggests a negative regulatory role of Gab1 in insulin-controlled glucose homeostasis. - To further determine the role of Gab1 in glucose homeostasis, Inventors performed a glucose tolerance test (GTT). Glucose tolerance tests were performed intravenously (IGTT), although the test can be performed orally (OGTT). In the current discovery, mice were fasted for 16 hours, and then given a solution containing a known amount of glucose via intra-peritoneal (IP) injection (2 g glucose per 1 kg body weight). Blood was obtained before IP injection of the glucose solution (time point 0), and was drawn again at 15, 30, 60 and 120 min (
time point FIG. 3 b); and thus the area under the glucose curve was significantly decreased (72% of control at 2-month; 59% at 1 year) for LGKO animals as compared to controls. In addition, the insulin response to the glucose load, measured at 60 and 120 min during the GTT, was significantly diminished in LGKO animals, with a decrease in the area under the curve by 44% (FIG. 3 b). Thus, selective deletion of hepatic Gab1 significantly improved glucose tolerance. In addition, the lower glucose response curve, in spite of significantly diminished insulin levels, also implicates enhanced insulin sensitivity. - To assess the potential difference in peripheral glucose disposal between the genotypes of mice, we first performed in vivo insulin tolerance tests. Insulin tolerance tests (ITT) were performed on randomly fed animals via IP delivery of a bolus of insulin (1 U insulin per kg of body weight), (Humulin, Eli Lilly and Company, Indianapolis, Ind. 46285). Blood glucose levels were measured at
time point FIG. 3 c, insulin's ability to reduce circulating glucose levels was similar between the genotypes at both ages. Since the insulin tolerance test is a relatively crude technique for assessment of insulin stimulated glucose disposal, the more accurate glucose clamp technique was used to quantitatively assess overall in vivo insulin action, quantify the rates of glucose disposal and hepatic glucose production. - Briefly, at 1 year of age each mouse was implanted with two catheters in the right jugular vein which were tunneled subcutaneously, exteriorized at the back of the neck, and encased in silastic tubing. Four days after surgery, animals were fasted for 6 hours and glucose turnover was measured in the basal state and during a hyperinsulinemic-euglycemic clamp. Following basal sampling (approximately 90 min), a constant infusion (5.micro.Ci/h) of [3-3H] D-glucose (NEN Life Science Products Inc.) was infused into one of the jugular cannulas. One hour after the start of the tracer infusion, a second basal blood sample was taken for measurement of glucose concentration and tracer specific activity as previously described 28. Following this, regular human insulin (12 mU·kg-1·min-1, Novolin R; Novo Nordisk Pharmaceutical Industries Inc.) combined with [3-3H] D-glucose (5.micro.Ci/h) was infused. Steady state was achieved by 80 minutes and held for the duration of the 120 minutes clamp. Following the steady state period (minimal of 30 minutes) at the end of the clamp, a final blood sample was taken for measurement of glucose turnover. Plasma glucose concentration was measured with a HemoCue glucose analyzer (Hemocue Inc., Lake Forrest, Calif. 92630). Circulating plasma human insulin following the clamp was measured using a radioimmunoassay kit (Linco Research, St. Charles, Mo. 63304, RIA Kit, Catalog No.: MENDO-75K). Plasma glucose specific activity was measured after deproteinization with barium hydroxide and zinc sulfate as previously described by our laboratory. Hepatic glucose production (HGP) and glucose disposal rate (GDR) were calculated at basal and during the 30-minute steady state portion of the glucose clamp. Tracer determined rates were quantified using the Steele equation for steady state conditions. Comparisons between the two groups were conducted using analysis variance (ANOVA), and values were presented as means±SEMs. Clamp techniques are well know in the art. (Miles, P. D., Barak, Y., He, W., Evans, R. M. & Olefsky, J. M. Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency. J Clin Invest 105, 287-92 (2000); Revers, R. R., Fink, R., Griffin, J., Olefsky, J. M. & Kolterman, O. G. Influence of hyperglycemia on insulin's in vivo effects in type II diabetes. J Clin Invest 73, 664-72 (1984); Steele, R. Influences of glucose loading and of injected insulin on hepatic glucose output. Ann N.Y. Acad Sci 82, 420-30 (1959).)
- Both groups of animals were clamped at the 6-h fasting blood glucose values, 125±2.4 mg/dl. The exogenous glucose infusion rate (GIR) required to maintain euglycemia during the glucose clamp was increased by ˜30% (P=0.0016) in LGKO mice (
FIG. 3 d). Similar to results for the insulin tolerance test (FIG. 3 c), no significant difference was observed between the genotypes with respect to insulin's ability to stimulate glucose disposal into skeletal muscle (IS-GDR,FIG. 3 e). However, we did detect more marked suppression of hepatic glucose production (HGP) from basal during the clamp in LGKO mice (FIGS. 3 f and 3 g), revealing enhanced hepatic insulin sensitivity. - Glucose is converted to fat in the liver, and triglycerides are released in blood by the liver. The amount of fasting triglycerides was slightly lower for both the 2-month-old (14.8% reduction) and 1-year-old (22.7% reduction) knockout mice (
FIG. 3 h). At 2-months-old, the difference was not significant (P=0.41), whereas at one-year-old of age, the difference was statistically significant (P<0.05). Thus, Gab1 deletion in the liver also changed hepatic lipid metabolism. - Inventors' have discovered that hypoglycemia and enhanced glucose tolerance in LGKO is related to the Gab1 actions in the liver. Gab1 promotes the Erk pathway in attenuating insulin-elicited signals through the IRS signalling pathway. Thus, Gab1 deficiency in hepatocytes removes Gab1 mediated attenuation of IRS, resulting in increased basal and insulin-stimulated Akt/PKB activity.
- To investigate the molecular basis for hypoglycemia and improved glucose tolerance, we examined the activity of Akt/PKB kinase, a critical enzyme in insulin signaling, by measuring levels of phospho-Akt (p-Akt) in both liver and muscle of wild-type and LGKO mice. Tissue lysates were made from the liver at 0, 2 and 5 min after insulin administration, and muscle lysates were prepared at 0, 4 and 8 min following insulin injection (
FIG. 4 a), and lysates were detected using immunoblot techniques as described hereinabove. Both basal and insulin-stimulated levels of p-Akt were higher in LGKO liver than that in wild-type, without a change in protein expression levels of Akt. Notably, elevated Akt activity was detected in the LGKO liver only, with no difference observed in skeletal muscle. Immunoblot and other techniques for measuring the level of protein in tissue samples are well known in the art. - Inventors measured the tyrosine phosphorylation status of the beta subunit of insulin receptor (IR.beta.) and observed its normal activation in LGKO liver as well as in muscle (
FIGS. 4 b and 4 c). The IR.beta. expression level was not changed either (FIG. 5 ). Therefore, the increased Akt activity can not be attributed to a change in IR.beta. activation or expression but is rather caused by a downstream event. - Inventors then examined the protein amounts of IRS-1, IRS-2, Shp-2, and the p85.alpha. subunit of PI3-kinase in both liver and muscle, and found no change in their expression in LGKO mice (
FIG. 5 ). However, using antibodies specific for the phosphorylated form of IRS-1 or IRS-2, Inventors discovered that enhanced tyrosine phosphorylation levels of both IRS-1 and IRS-2 were detected in the LGKO liver with or without insulin stimulation (FIGS. 4 c and 4 d). IRS-1 tyrosine phosphorylation was the most affected, with a 2.0 fold increase at the basal level and a 1.4 fold increase after insulin stimulation, whereas it was about 1.4 fold improved at both conditions for IRS-2. Consistently, higher amounts of p85 were detected in complex with IRS-1 and IRS-2 in Gab1-deficient hepatocytes, under both control and insulin-stimulated status (FIGS. 4 c and 4 d). Thus, Gab1 acts to attenuate insulin-triggered signals going through both IRS-1 and IRS-2, and deletion of Gab1 in the liver leads to augmented activation of the IRS proteins, which results in promotion of the PI3K/Akt pathway. The binding of IRS-1, -2 to IR.beta. is not affected by Gab1 deletion (FIG. 4 d), excluding the possibility of a competition between IRS and Gab1 for binding IR.beta. Unlike the IRS proteins, Gab1 is weakly tyrosine-phosphorylated following insulin stimulation (FIGS. 4 e, 4 f and 4 g), despite high levels of Gab1 phosphorylation being detected following induction by injection of EGF or peroxo-vanadate (an agent known to induce tyrosine phosphorylation). Neither phosphorylation of the p85 binding motif on Gab1 (p-YXXM), nor association of Gab1 with p85 was detected in insulin treated liver (FIG. 4 g), suggesting that Gab1 may not be found directly involved in insulin stimulated pI3K/Akt pathway. Instead it appears that Gab1 has a negative effect on insulin stimulated IRS activation and thus deletion of Gab1 in the liver leads to augmented IRS tyrosine phosphorylation. This observation is contrary to what would be expected if Gab1 was directly involved in modulation of PI3K/Akt pathway in response to insulin. - Those of ordinary skill in the art are familiar with a variety of techniques for detecting phosphorylation of an amino acid residue within a protein or peptide fragment. Briefly, and by way of example only, wild-type mice were injected via vena cava with a saline solution (control), insulin (5 U), EGF (100 μg), or peroxo-vanadate. Liver extracts were prepared 2 min after injection; immunoprecipitated with Gab1 antibody; and immunoblotted with antibodies against either phosphotyrosine (PY), Gab1, phospho-(Tyr) p85 PI3K (p-YXXM), or p85. Peroxo-vanadate solution was prepared following a procedure published previously (S. J. Ruff, K. Chen, S. Cohen, J Biol Chem 272, 1263-7 (Jan. 10, 1997)).
- Vena cava injection of insulin dramatically induced the activation of extracellular signal-regulated kinase (Erk) in the liver in vivo (
FIG. 4 h). However, the insulin-stimulated Erk activity was abolished in Gab1 deficient hepatocytes (FIG. 4 h). This result suggests that Gab1, rather than IRS protein, plays a critical role in mediating insulin-stimulated activation of the Erk pathway in hepatocytes. It was previously reported that serine phosphorylation of IRS-1 by Erk down regulated its tyrosine phosphorylation and association with p85 ((Mothe, I. & Van Obberghen, E. J Biol Chem 271: 11222-7 (1996), De Fea, K. & Roth, R. A. Biochemistry 36: 12939-47 (1997), De Fea, K. & Roth, R. A. J Biol Chem 272: 31400-6 (1997)). Using an antibody specific for phospho-serine 612 (p-IRS-1.sup.S612), Inventor detected insulin-induced phosphorylation of IRS-1 on this amino acid residue, a known negative regulatory site on IRS-1 for insulin signaling (De Fea, K. & Roth, R. A. Biochemistry 36, 12939-47 (1997)). Notably, this serine-phosphorylation event was abolished in Gab1-deficient hepatocytes (FIG. 4 h). Consistently, injection of MEK inhibitors (PD98059 or U0126. Cell Signaling Technologies, Beverly, Mass., Cat. Nos.: 9900S and 9903, respectively) also attenuated Erk activation as well as phosphorylation of IRS-1 on Ser612 (FIG. 4 i). - Inventors have discovered and herein disclosed that Gab1 is the primary mediator for insulin-stimulated Erk activation, which leads to serine phosphorylation of IRS-1 and attenuation of its tyrosine phosphorylation. This, in turn, results in down-regulation of the IRS/PI3K/Akt pathway. This negative feedback loop in hepatocytes is a critical molecular mechanism for glucose homeostasis, as controlled by insulin (
FIG. 6 ). Interestingly, the negative regulatory role of Gab1 in glucose metabolism is connected with its positive effect in mediating cell mitogenesis via the Erk pathway. Thus, pharmaceutical interference of the Gab1 activity in insulin signaling not only reduces blood glucose levels but also may suppress unwanted mitogenic activities in the liver. - Dysregulation of the glucose homeostasis pathway can lead to numerous disorders ranging from altered blood pressure to diabetes. Diabetes mellitus is the most common public health problem worldwide, affecting over 5% of the population in western countries. Ninety-five percent (95%) of the cases are classified as type II or non-insulin-dependent diabetes mellitus, which results from resistance to insulin activity (Kahn, B. B. & Rossetti,
L. Nat Genet 20, 223-5 (1998), Taylor, S. I. Cell 97, 9-12 (1999)). To this end, search for negative regulators of the glucose homeostasis pathway is of particular interests in development of therapeutic strategies for related diseases. - Through Inventor's novel discovery of the Gab1 signalling pathway, Gab1 presents as an attractive target for addressing these goals. The negative regulatory role of Gab1 in glucose homeostasis is connected with its positive effect in mediating cell mitogenesis via the Erk pathway. Disruption of the Gab1 activity in insulin signalling may not only reduce blood glucose level but also may suppress unwanted mitogenic activities in the liver, thereby preventing hepatic carcinogenesis.
- Thus, Inventors have uncovered a novel balancing mechanism for control of insulin signal strength in liver via the actions of Gab1. Inventors' discovery leads to a novel method for discovering new therapeutic modulators for treating type II diabetes mellitus, and other regulatory disorders of the glucose homeostasis pathway. Inventors' discovery also leads to a novel method for diagnosing the origin of disorders related to glucose homeostasis dysregulation, and developing specific treatments therefore.
- While the present invention has been described in some detail for purposes of clarity and understanding, one skilled in the art will appreciate that various changes in form and detail can be made without departing from the true scope of the invention.
- High Throughput Screening techniques are well known in the art and applicable to methods using Inventors' discovery. The number of different candidate compounds used to test in the methods of the invention will depend on the application of the method For example, one or a small number of candidate compounds can be advantageous in manual screening procedures, or when it is desired to compare efficacy among several predicted ligands, agonists or antagonists. However, it is generally understood that the larger the number of candidate compounds, the greater the likelihood of identifying a compound having the desired activity in a screening assay. Additionally, large numbers of compounds can be processed in high-throughput automated screening assays. Therefore, “one or more candidate compounds” can be, for example, 2 or more, such as 5, 10, 15, 20, 50 or 100 or more different compounds, such as greater than about 103, 105 or 107 different compounds, which can be assayed simultaneously or sequentially
- The following non-limiting examples are useful in describing Inventor's discovery, and are in no way meant to limit the current invention. Those of ordinary skill in the art will readily adopt the underlying principles of Inventor's discovery to design a variety of screening assays without departing from the spirit of the current invention.
- A first screening assay takes advantage of the methods and procedures described above. In this example, LGKO and WT mice are generated using the previously described procedures. Blood glucose levels, Glucose tolerance tests and Insulin tolerance tests are performed at
time point 0, as described. The mice are then given a bolus of glucose. The control group comprises both WT mice and the LGKO mice, which receive the bolus of glucose alone. Similarly, the test group comprises WT and the LGKO mice; however, the test group receives a bolus of glucose and one or more candidate compounds. A candidate compound can be a naturally occurring macromolecule, such as a polypeptide, amino acid, nucleic acid, carbohydrate, lipid, or any combination thereof. A candidate compound also can be a partially or completely synthetic derivative, analog or mimetic of such a macromolecule, or a small organic molecule prepared by combinatorial chemistry methods. Candidate compounds can be given concurrently with the bolus of glucose or at a time point before or after the administration of said bolus of glucose. The Blood glucose levels, Glucose tolerance tests and Insulin tolerance tests are again performed, this time attime points - Measurements received from the control group establish baseline glucose levels, glucose tolerance and baseline insulin tolerance. As described above, there is a difference in the blood glucose levels and in glucose tolerance, but not insulin tolerance, between the WT and LGKO mice, thus the control group will establish data parameters for mice with functional Gab1 and with a knockout Gab1.
- The test group will receive a glucose bolus and one or more candidate compounds. Each candidate compound will be tested in WT and LGKO mice. Candidate compounds that modulate the glucose homeostasis pathway are useful in treating the conditions associated with dysregulation of said glucose homeostasis pathway. For example, LGKO mice receiving a candidate compound that increases blood glucose levels reveal an ideal candidate modulator for treating hypoglycemia. Similarly, WT mice receiving a candidate compound that decreases blood glucose levels reveal an ideal candidate modulator for treating hyperglycemia. Glucose tolerance modulators are also discovered using this screening method.
- Those of skill in the art will readily use Inventor's disclosure and will design numerous animal models to screen candidate compounds for modulators of the glucose homeostasis pathway. Such uses are all within the spirit of the current invention.
- In a second example, test agents are screened to see if said test agent is capable of modulating Gab1 mediated Erk1/2 activity. Those of ordinary skill in the art will readily uncover this same information using a variety of methods; however, in this example hepatic cell lines containing the Gab1 mediated glucose homeostasis pathway are used.
- Briefly, hepatic cells are plated in a multi-well cell culture plate containing 96 wells, 384 wells, 1594 or other commercially available well numbers, and are incubated according to well known procedure. Otherwise identical wells are then either exposed to one or more candidate compounds in a glucose solution (test wells) or are exposed to glucose solution alone (control wells). A candidate compound can be a naturally occurring macromolecule, such as a polypeptide, amino acid, nucleic acid, carbohydrate, lipid, or any combination thereof. A candidate compound also can be a partially or completely synthetic derivative, analog or mimetic of such a macromolecule, or a small organic molecule prepared by combinatorial chemistry methods.
- The wells are immediately and incrementally assayed for glucose concentration. In this situation, the response of the test cell to a candidate compound is compared to the response (or lack of response) of the control cell to the same compound under substantially the same reaction conditions. Candidate compounds that reduce the level of glucose in the test well as compared to the control are considered to negatively modulate Gab1 mediated Erk1/2 activity, thereby leading to a hypoglycemic environment. Conversely, candidate compounds that result in a higher level of glucose in the test well as compared to the control are considered to positively modulate Gab1 mediated Erk1/2 activity, thereby leading to a hyperglycemic environment.
- Candidate compounds shown to modulate Gab1 mediated Erk1/2 activity are useful in treating the conditions associated with dysregulation of the glucose homeostasis pathway.
- In an alternative embodiment of Screening Assay Two, hepatic cell lines comprise either a wild type Gab1 or a Gab1 knockout. In this embodiment, the assay is performed as is Screening Assay Two: cells are plated in wells; the wells are exposed to glucose alone (control well) or glucose and one or more candidate compounds (test wells); and subsequent glucose concentration data is acquired.
- In this embodiment, the control wells present data for the Gab1 mediated glucose homeostasis pathway wherein either Gab1 is functional or wherein Gab1 is knocked out. Candidate compounds that cause a decrease in glucose concentration in the wild type wells function to modulate the Gab1 mediated glucose homeostasis pathway in a manner similar to when Gab1 is knocked out. These modulators are useful for treating hyperglycemia. Conversely, candidate compounds that cause an increase in glucose concentration in the LGKO wells function to modulate the Gab1 mediated glucose homeostasis pathway in a manner similar to when Gab1 is functionally present.
- In a fourth example, candidate compounds are screened to determine whether said candidate compound is capable of modulating Gab1 wherein said screening method includes (a) contacting Gab1 under conditions suitable to promote MapK activation by insulin; (b) measuring the activity of insulin-stimulated MapK; (c) contacting Gab1 with a candidate compound; and (d) determining the ability of the candidate compound to modulate glucose homeostasis, where modulation of insulin-stimulated MapK activity indicates that the candidate compound is an effective compound that modulates glucose homeostasis.
- For example, such a screening method can include a hepatic cell line comprising the Gab1 signaling pathway. The hepatocytes are plated in a cell culture well under suitable conditions. Such cell culture wells may be part of a multi-well plate having 96-wells, 384-wells or any number of wells commercially available. Those of skill in the art will readily adapt the current example to high throughput screening. Such applications are anticipated by the current disclosure.
- The wells are designated as either negative control (cell media only); positive control (cell media and insulin) or test wells type A (cell media, insulin and candidate compound) and test wells type B (cell media and candidate compound). The cells are incubated under suitable conditions along with negative control media, positive control media, type A media or type B media. Following incubation, the cells are lysed at the optimal time and the extracts are assayed for MapK (Erk1/2) activity using immunoblot techniques. An antibody specific for phospho serine 612 of IRS-1 is used to detect insulin mediated activity of Erk1/2 t. In short, wells are stained for IRS-1 phosphorylation using p-IRS-1.sup.Ser612 antibodies followed by Cy3 conjugated anti-goat IgG (Cell Signaling Technologies, Beverly, Mass.). Fluorescent images can be collected and analyzed using, for example, MRC-1024 MP laser-scanning confocal microscope, and the images then compared.
- The phosphorylation of IRS-1 in the presence of a candidate compound is compared to the control wells. Data acquired from the control wells establishes the degree of Gab1 mediated glucose homeostasis pathway activity in the presence and absence of insulin. Data from the test wells can be compared to the control wells. Candidate compounds causing an increase or decrease in insulin mediated activity of Erk1/2, as compared to control wells, determined by relative levels of phosphorylation at Ser612 residue of IRS-1, are useful as modulators of the Gab1 mediated glucose homeostasis pathway. Furthermore, the action of these modulators is further elucidated in that those that activate the Gab1 pathway in the absence of insulin are useful for treating insulin production and/or release mediated disorders, while those that act in the presence of insulin are useful for disorder occurring despite the presence of insulin. Modulators that increase IRS-1 phosphorylation are useful for treating hypoglycemia, while those that reduce IRS-1 phosphorylation are useful for treating hyperglycemia.
- The current invention is additionally useful in diagnosing whether a dysregulation of the glucose homeostasis pathway is related to the Gab1 signaling pathway. For example, using the technique described in Screening Assay Two, hepatic cells obtained from the liver biopsy of a patient suffering from a disorder related to glucose homeostasis dysregulation can be assayed.
- Biopsied hepatic cells are plated in a cell culture plate, which may be multi well containing 96 wells, 384 wells, 1594 wells or other commercially available well numbers, and are incubated according to well known procedure. Otherwise identical wells are then either exposed to Gab1 modulators in a glucose solution (test wells) or are exposed to glucose solution alone (control wells). Gab1 modulators, as used in this Diagnostic Assay, are those that have been identified to restore glucose homeostasis in LGKO mice, or other Gab1 deficient systems.
- The wells are immediately and incrementally assayed for glucose concentration. In this situation, the response of the test cell to the modulator is compared to the response in the control cell under substantially the same reaction conditions. If the Gab1 modulator causes a restoration of glucose homeostasis in said test cell, then the diagnosis and subsequent treatments can be tailored to treating a Gab1 deficiency.
- Methods of using the compounds and pharmaceutical compositions of the invention are also provided herein. The methods involve both in vitro and in vivo uses of the compounds and pharmaceutical compositions for altering preferred nuclear receptor activity, in a cell type specific fashion.
- In certain embodiments, the claimed methods involve the discovery and use of modulating compounds including agonists, antagonists, ligands, small molecules, peptides and nucleic acid molecules.
- Once identified as a modulator using a method of the current invention, an agent can be put in a pharmaceutically acceptable formulation, such as those described in Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Co., Easton, Pa. (1990), incorporated by reference herein, to generate a pharmaceutical composition useful for specific treatment of diseases and pathological conditions.
- Agents identified by the methods taught herein can be administered to a patient either by themselves, or in pharmaceutical compositions where it is mixed with suitable carriers or excipient(s). In treating a patient exhibiting a disorder of interest, a therapeutically effective amount of agent or agents such as these is administered. A therapeutically effective dose refers to that amount of the agent resulting in amelioration of symptoms or a prolongation of survival in a patient.
- The agents also can be prepared as pharmaceutically acceptable salts. Examples of pharmaceutically acceptable salts include, but are not limited to acid addition salts such as those containing hydrochloride, sulfate, phosphate, sulfamate, acetate, citrate, lactate, tartrate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate, cyclohexylsulfamate and quinate. Such salts can be derived using acids such as hydrochloric acid, sulfuric acid, phosphoric acid, sulfamic acid, acetic acid, citric acid, lactic acid, tartaric acid, malonic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, p-toluenesulfonic acid, cyclohexylsulfamic acid, and quinic acid.
- Pharmaceutically acceptable salts can be prepared by standard techniques. For example, the free base form of the agent is first dissolved in a suitable solvent such as an aqueous or aqueous-alcohol solution, containing the appropriate acid. The salt is then isolated by evaporating the solution. In another example, the salt is prepared by reacting the free base and acid in an organic solvent.
- Carriers or excipients can be used to facilitate administration of the agent, for example, to increase the solubility of the agent. Examples of carriers and excipients include calcium carbonate, calcium phosphate, various sugars or types of starch, cellulose derivatives, gelatin, vegetable oils, polyethylene glycols and physiologically compatible solvents.
- For applications that require the compounds and compositions to cross the blood-brain barrier, or to cross the cell membrane, formulations that increase the lipophilicity of the compound are particularly desirable. For example, the compounds of the invention can be incorporated into liposomes (Gregoriadis, Liposome Technology, Vols. I to III, 2nd ed. (CRC Press, Boca Raton Fla. (1993)). Liposomes, which consist of phospholipids or other lipids, are nontoxic, physiologically acceptable and metabolizable carriers that are relatively simple to make and administer. Additionally, the therapeutic compound can be conjugated to a peptide that facilitates cell entry, such as penetratin (also known as Antennapedia peptide), other homeodomain sequences, or the HIV protein Tat.
- Toxicity and therapeutic efficacy of such agents can be determined by standard pharmaceutical procedures in cell cultures or experimental animals, e.g., for determining the LD50 (the dose lethal to 50% of the population) and the ED50 (the dose therapeutically effective in 50% of the population). The dose ratio between toxic and therapeutic effects is the therapeutic index and it can be expressed as the ratio LD50/ED50. Agents which exhibit large therapeutic indices are preferred The data obtained from these cell culture assays and animal studies can be used in formulating a range of dosage for use in humans. The dosage of such agents lies preferably within a range of circulating concentrations that include the ED50 with little or no toxicity. The dosage may vary within this range depending upon the dosage form employed and the route of administration utilized.
- For any agent identified by the methods taught herein, the therapeutically effective dose can be estimated initially from cell culture assays. For example, a dose can be formulated in animal models to achieve a circulating plasma concentration range that includes the IC50 as determined in cell culture (i.e., the concentration of the test agent which achieves a half-maximal disruption of the protein complex, or a half-maximal inhibition of the cellular level and/or activity of a complex component). Such information can be used to more accurately determine useful doses in humans. Levels in plasma may be measured, for example, by HPLC.
- The exact formulation, route of administration and dosage can be chosen by the individual physician in view of the patient's condition. (See e.g. Fingl et al., in The Pharmacological Basis of Therapeutics, Ch. 1 p. 1 (1975)). It should be noted that the attending physician would know how to and when to terminate, interrupt, or adjust administration due to toxicity, or to organ dysfunctions. Conversely, the attending physician would also know to adjust treatment to higher levels if the clinical response were not adequate (precluding toxicity). The magnitude of an administrated dose in the management of the disorder of interest will vary with the severity of the condition to be treated and to the route of administration. The severity of the condition may, for example, be evaluated, in part, by standard prognostic evaluation methods. Further, the dose and perhaps dose frequency, will also vary according to the age, body weight, and response of the individual patient. A program comparable to that discussed above may be used in veterinary medicine.
- Depending on the specific conditions being treated, such agents may be formulated and administered systemically or locally. Techniques for formulation and administration may be found in Remington's Pharmaceutical Sciences, 18th ed., Mack Publishing Co., Easton, Pa. (1990). Suitable routes may include oral, rectal, transdermal, vaginal, transmucosal, or intestinal administration; parenteral delivery, including intramuscular, subcutaneous, intramedullary injections, as well as intrathecal, direct intraventricular, intravenous, intraperitoneal, intranasal, or intraocular injections, just to name a few.
- For injection, the agents may be formulated in aqueous solutions, preferably in physiologically compatible buffers such as Hanks's solution, Ringer's solution, or physiological saline buffer. For such transmucosal administration, penetrants appropriate to the barrier to be permeated are used in the formulation. Such penetrants are generally known in the art.
- Use of pharmaceutically acceptable carriers to formulate the agents herein disclosed into dosages suitable for systemic administration is contemplated. With proper choice of carrier and suitable manufacturing practice, these agents, in particular, those formulated as solutions, may be administered parenterally, such as by intravenous injection. The agents can be formulated readily using pharmaceutically acceptable carriers well known in the art into dosages suitable for oral administration. Such carriers enable the agents of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
- Agents intended to be administered intracellularly may be administered using techniques well known to those of ordinary skill in the art. For example, such agents may be encapsulated into liposomes, then administered as described above. Liposomes are spherical lipid bilayers with aqueous interiors. All molecules present in an aqueous solution at the time of liposome formation are incorporated into the aqueous interior. The liposomal contents are both protected from the external microenvironment and, because liposomes fuse with cell membranes, are efficiently delivered into the cell cytoplasm. Additionally, due to their hydrophobicity, small organic molecules may be directly administered intracellularly.
- Pharmaceutical compositions suitable for use in the context of the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein. In addition to the active ingredients, these pharmaceutical compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active agents into preparations which can be used pharmaceutically. The preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions. The pharmaceutical compositions contemplated by the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levitating, emulsifying, encapsulating, entrapping or lyophilizing processes.
- Pharmaceutical formulations for parenteral administration include aqueous solutions of the active agents in water-soluble form. Additionally, suspensions of the active agents may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the agents to allow for the preparation of highly concentrated solutions.
- Pharmaceutical preparations for oral use can be obtained by combining the active agents with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores. Suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP). If desired, disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
- Dragee cores are provided with suitable coatings. For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures. Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active agent doses.
- Pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol. The push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers. In soft capsules, the active agents may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols. In addition, stabilizers may be added.
- Some methods of delivery that may be used include:
- a. encapsulation in liposomes,
- b. transduction by retroviral vectors,
- c. localization to nuclear compartment utilizing nuclear targeting site found on most nuclear proteins,
- d. transfection of cells ex vivo with subsequent reimplantation or administration of the transfected cells,
- e. a DNA transporter system.
Claims (20)
1. A method of identifying a modulator of Gab1 comprising:
providing a first group comprising cells that express Gab1 protein and a second group comprising cells modified to lack Gab1 protein expression;
contacting said first group and second group with a candidate agent;
comparing the extracellular glucose concentration of said first and second groups after contact with said candidate agent to a baseline value indicated by the difference in extracellular glucose concentration between the first and second groups without contact with said candidate agent; and
identifying the candidate agent as a modulator of Gab1 if a change in glucose concentration between the first and second groups is found after contact with the candidate agent compared to the baseline value.
2. The method of claim 1 , wherein the cells of the first and second groups comprise mammalian cells.
3. The method of claim 2 , wherein the cells of the first and second groups comprise murine cells.
4. The method of claim 3 , wherein the cells modified to lack Gab1 protein expression are from a transgenic mouse whose genome comprises a homozygous disruption of the endogenous Gab1 gene.
5. The method of claim 1 , wherein the cells of said first and second groups are from the same organ type.
6. The method of claim 4 , wherein the organ type is liver.
7. The method of claim 1 , wherein said providing and said contacting are performed in vitro.
8. The method of claim 1 , wherein said providing and said contacting are performed in vivo.
9. The method of claim 8 , wherein said first and second groups are mice.
10. The method of claim 9 , wherein said second group is a transgenic mouse whose genome comprises a homozygous disruption of the endogenous Gab1 gene.
11. The method of claim 10 , further comprising administering a known amount of glucose to the mice.
12. The method of claim 11 , wherein the extracellular glucose concentration is measured as plasma glucose levels.
13. The method of claim 1 , wherein the candidate agent is identified as a positive modulator of Gab1 if said change in glucose concentration is an increase.
14. The method of claim 1 , wherein the candidate agent is identified as a negative modulator of Gab1 if said change in glucose concentration is a decrease.
15. A transgenic mouse whose genome comprises a homozygous disruption of the endogenous Gab1 gene, wherein said disruption results in the functional inactivation of the Gab1 gene, and wherein said mouse exhibits hypoglycemia relative to a mouse whose genome comprises the functional endogenous Gab1 gene.
16. The transgenic mouse of claim 15 , wherein the homozygous disruption is specifically in the hepatic cells of the mouse.
17. The transgenic mouse of claim 15 , wherein the disruption in the Gab1 gene is a deletion of SEQ ID NO: 3.
18. The transgenic mouse of claim 17 , wherein the Gab1 gene is replaced with a replacement gene.
19. The transgenic mouse of claim 18 , wherein the replacement gene comprises a neomycin resistance gene.
20. The transgenic mouse of claim 17 , wherein the replacement gene further comprises a thymidine kinase gene.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/879,946 US20110067126A1 (en) | 2003-11-12 | 2010-09-10 | Gab1 involvement in glucose homeostasis regulation by hepatocytes |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51935803P | 2003-11-12 | 2003-11-12 | |
US10/987,384 US7794956B2 (en) | 2003-11-12 | 2004-11-12 | Gab1 involvement in glucose homeostasis regulation by hepatocytes |
US12/879,946 US20110067126A1 (en) | 2003-11-12 | 2010-09-10 | Gab1 involvement in glucose homeostasis regulation by hepatocytes |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/987,384 Continuation US7794956B2 (en) | 2003-11-12 | 2004-11-12 | Gab1 involvement in glucose homeostasis regulation by hepatocytes |
Publications (1)
Publication Number | Publication Date |
---|---|
US20110067126A1 true US20110067126A1 (en) | 2011-03-17 |
Family
ID=34841059
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/987,384 Expired - Fee Related US7794956B2 (en) | 2003-11-12 | 2004-11-12 | Gab1 involvement in glucose homeostasis regulation by hepatocytes |
US12/879,946 Abandoned US20110067126A1 (en) | 2003-11-12 | 2010-09-10 | Gab1 involvement in glucose homeostasis regulation by hepatocytes |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/987,384 Expired - Fee Related US7794956B2 (en) | 2003-11-12 | 2004-11-12 | Gab1 involvement in glucose homeostasis regulation by hepatocytes |
Country Status (1)
Country | Link |
---|---|
US (2) | US7794956B2 (en) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8307068B2 (en) * | 2009-06-17 | 2012-11-06 | Volonics Corporation | Supervised access computer network router |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6133428A (en) * | 1995-08-22 | 2000-10-17 | Thomas Jefferson University | Gab1, a Grb2 binding protein, and compositions for making and methods of using the same |
-
2004
- 2004-11-12 US US10/987,384 patent/US7794956B2/en not_active Expired - Fee Related
-
2010
- 2010-09-10 US US12/879,946 patent/US20110067126A1/en not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6133428A (en) * | 1995-08-22 | 2000-10-17 | Thomas Jefferson University | Gab1, a Grb2 binding protein, and compositions for making and methods of using the same |
Non-Patent Citations (1)
Title |
---|
Holgado-Madruga et al (Nature, 1996, 379, 560 - 564 * |
Also Published As
Publication number | Publication date |
---|---|
US20050183144A1 (en) | 2005-08-18 |
US7794956B2 (en) | 2010-09-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Mori et al. | Critical roles for the TSC-mTOR pathway in β-cell function | |
JP4518378B2 (en) | Mnk kinase homologous proteins involved in the regulation of energy homeostasis and organelle metabolism | |
US11931402B2 (en) | Compositions for treating heart disease by inhibiting the action of mAKAP-β | |
JPWO2006134692A1 (en) | Vascular structure stabilizer and angiogenic agent targeting RAMP2 | |
US6605753B1 (en) | Protein tyrosine phosphate-1B (PTP-1B) deficient mice and uses thereof | |
CA2388180C (en) | Inhibitors of the inositol polyphosphate 5-phosphatase ship2 molecule | |
WO2004026285A2 (en) | Compositions and methods for treating heart disease | |
Barwe et al. | Dysfunction of ouabain-induced cardiac contractility in mice with heart-specific ablation of Na, K-ATPase β1-subunit | |
US20110067126A1 (en) | Gab1 involvement in glucose homeostasis regulation by hepatocytes | |
US8598146B2 (en) | Methods for identifying modulators of protein kinase C-epsilon (PKCε) and method of treatment of aberrant glucose metabolism associated therewith | |
US20150313961A1 (en) | Materials and Methods for Regulating Whole Body Glucose Homeostasis | |
US20080104718A1 (en) | Transgenic Non-Human Animal Models of Ischemia-Reperfusion Injury and Uses Thereof | |
JP2007505628A (en) | Modulation of cardiac contractility and heart failure tendency | |
US20240216466A1 (en) | COMPOSITIONS FOR TREATING HEART DISEASE BY INHIBITING THE ACTION OF mAKAP-beta | |
CA2606228A1 (en) | Methods and compositions for using alveolar macrophage phospholipase a2 | |
US20080268445A1 (en) | Ant2 Conditional Knockout Mouse and Methods | |
US20050091704A1 (en) | Ant2 conditional knockout mouse and methods | |
Petersen | The Insulin Receptor as a Locus of Control in Hepatic Insulin Resistance | |
Kittikulsuth et al. | Genetic Manipulation of the Endothelin System | |
Poy | CEACAM1: A novel regulator of insulin clearance and action | |
EP1908827A2 (en) | Regulation of cardiac contractility and heart failure propensity | |
Lu | Regulation of sterol regulatory element binding proteins by hemodynamic forces and hormones: Implications of lipid metabolism in vasculature | |
Patel | A role for CEACAM2 in insulin homeostasis and action | |
JP2004154129A (en) | Stress-associated endoplasmic reticulum protein serp1 gene defective model non-human animal | |
CA2613348A1 (en) | Transgenic mice carrying hp-2 gene and uses as models for vascular diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |
|
AS | Assignment |
Owner name: NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR, MARYLAND Free format text: CONFIRMATORY LICENSE;ASSIGNOR:SANFORD BURNHAM PREBYS MEDICAL DISCOVERY INSTITUTE;REEL/FRAME:051941/0198 Effective date: 20200124 |